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Summary  
Atherosclerosis is a chronic disease characterized by lipid retention and inflammation in 
the arterial intima. High density lipoproteins (HDL) and its major apolipoprotein (apoA-I) 
exert diverse potentially atheroprotective functions: For example, they reduce oxidative 
damage, correct endothelial dysfunction, inhibit inflammation and mediate reverse 
cholesterol transport. The latter process involves the removal of excess cholesterol from 
macrophage foam cells in the arterial wall and its delivery to the liver for biliary excretion.  
This and others anti-atherogenic functions of HDL must be exerted in the arterial wall 
rather than in the plasma compartment. Therefore HDL or apoA-I must pass the 
endothelial barrier to get access to the foam cells. In previous work, it has been shown 
in cell culture experiments that endothelial cells transcytose HDL and apoA-I by distinct 
specific mechanisms involving the scavenger receptor (SR)-BI, the ATP binding cassette 
transporters (ABC) G1 for HDL and the ABCA1 as well as the ectopic -ATPase for 
apoA-I. However little is known on how inflammation influences this trans-endothelium 
transport.  Therefore we analyzed the role of the cytokines: interleukins (IL)-6, IL-1 and 
tumor necrosis factor (TNF) on the trans-endothelial transport of HDL and apoA-I.  
In the present thesis we demonstrated that the binding, internalization and trans-
endothelial transport of HDL is influenced cytokine dependently. IL-6 increased the 
binding and transport of HDL without changing the expression of SR-BI and ABCG1. 
Therefore we characterized endothelial lipase (EL) a known HDL binding protein 
expressed by endothelial cells.  Here we showed that IL-6 induces EL and that 
pharmacological inhibition of EL after IL-6 stimulation reverses the inducing effect of IL-6 
on HDL binding and transport.  
In addition upon stimulation of TNF and IL-1 primary endothelial cells demonstrated a 
decrease of apoA-I binding and transport possibly due to decreasing cell surface 
expression of -ATPase. Furthermore TNF increased binding of HDL but reduced its 
transport. This discrepancy between binding and transport was not explained by 
enhanced cellular degradation but by reduced internalization.  
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The physiological relevance of in vitro studies is often contested. Therefore we 
characterized a novel 3D model based on the co-culture of endothelial cells and smooth 
muscle cells grown under flow condition. Histological analyses revealed that the artery 
equivalent mimick the structrure of a native artery. This raises the question, whether 
tissue engineered vascular grafts can serve as a model to study the development of 
atherosclerosis under flow conditions in vitro.  
We demonstrated here the feasibility of this vascular graft model to record the insudation 
and accumulation of both low (LDL) and high density lipoprotein (HDL) within the arterial 
wall. In addition monocytes circulating through the system adhered to the endothelium 
after prelimary treatment with either TNF or LDL and they transmigrated into the intima. 
 
In conclusion our work suggests that inflammatory cytokines modulate HDL and apoA-I 
tansport through endothelial cells. In addition we revealed EL as a novel HDL binding 
partner in endothelial cells, which is modulated by cytokines and contributes to the trans-
endothelial transport of HDL. Furthermore the novel engineered model appears to be 
suitable for studying atherosclerosis development in vitro. 
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Zusammenfassung  
Atherosklerose stellt eine chronische Erkrankung dar, welche sich durch die 
Ansammlung von Lipiden sowie einer Entzündung im Bereich der inneren Gefässschicht 
von Arterien auszeichnet. High density lipoproteins (HDL) und sein wichtiges 
Apolipoprotein apoA-I haben diverse, potentiell atheroprotektive Funktionen: Zum 
Beispiel reduzieren sie oxidativen Stress, korrigieren endotheliale Fehlfunktion, hemmen 
Entzündung und könnten für den reversiblen Cholesterol-transport verantwortlich sein. 
Letzerer involviert die Entfernung von überschüssigem Cholesterol aus Makrophagen 
(sog. Schaumzellen) in den Arterienwänden und deren Transport zur Leber für die 
biliäre Ausscheidung. Diese und weitere anti-atherogene Funktionen von HDL werden in 
den Arterienwänden und nicht im Blutplasma vermutet. Daher müssen HDL und apoA-I 
die endotheliale Barriere passieren, um Zugang zu den Schaumzellen zu erlangen. 
Vorstudien konnten in Zellkulturexperimenten zeigen, dass Endothelzellen apoA-I und 
HDL via Transzytose mit Hilfe des Scanvanger Rezeptors (SR)-BI, des ATP binding 
cassette transporters (ABC) G1 für HDL, des ABCA1 sowie der ektopen -ATPase für 
apoA-I transportieren. Es ist jedoch wenig darüber bekannt inwiefern die Entzünung 
diesen transendothelialien Transport beinflussen kann. Deshalb untersuchten wir in 
unseren Experimenten die Rolle der folgenden Zytokine und deren Einfluss auf den 
transendothelialen Transport von HDL und apoA-I: (IL)-6, IL-1β, und tumor necrosis 
factor (TNFα). 
Die vorliegende Arbeit zeigt, dass die Bindung, Internalisierung und der 
transendotheliale Transport von HDL von Zytokinen beeinflusst wird. Dabei erhöht IL-6 
die Bindung und den Transport von HDL ohne jedoch die Expression von SR-BI und 
ABCG1 zu verändern. In der Folge charakterisierten wir die endotheliale Lipase (EL), 
welche ein bekanntes HDL-Bindungsprotein darstellt und durch Endothelzellen 
exprimiert wird. Wir konnten ferner zeigen, dass IL-6 EL induziert und die 
pharmakologische Hemmung von EL nach Stimulation mit IL-6 den induzierenden Effekt 
von IL-6 auf die HDL-Bindung bzw. den Transport umkehrt. 
Zudem zeigten primäre Endothelzellen nach einer Stimulation durch TNFα und IL-1β 
eine Abnahme der Bindung und des Transportes von apoA-I, welche möglicherweise auf 
die Abnahme der Expression von β-ATPase zurückzuführen ist. Weiters beobachteten 
wir, dass TNFα eine Zunahme der Bindung von HDL bewirkte, jedoch dessen Transport 
verringerte. Diese Diskrepanz zwischen Bindung und Transport kann nicht mit erhöhtem 
zellulärem Abbau sondern vielmehr mit reduzierter Internalisierung erklärt werden. 
Die physiologische Relevanz dieser in vitro Studien im Bereich der Atherosklerose-
Forschung ist Gegenstand ausgedehnter Diskussionen und wird oftmals kritisiert. Wir 
haben deshalb ein neuartiges 3D-Modell entwickelt, welches auf der Co-Kultur von 
Endothelzellen und glatten Muskelzellen basiert und die Komponente des Flusses 
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miteinschliesst. Histologische Analysen dieser Konstrukte zeigten, dass die 
hergestellten Strukturen im Aufbau einer nativen Arterie ähneln. Dies entwirft die 
Fragestellung, ob diese „tissue engineerten“ Gefässe als Modelle für die 
Atheroskleroseforschung unter Einfluss von Flussbedingungen dienen könnten. 
In der vorliegenden Arbeit konnten wir erste Schritte zur Entwicklung eines derartigen in 
vitro Modelles tätigen und zahlreiche Prozesse beobachten, welche im Rahmen der 
Atherosklerose-Entstehung in vivo relevant sind: Die Insudation von LDL und HDL in die 
Arterienwand, sowie die durch TNFα/LDL stimulierte Adhäsion und Transmigration von 
Monozyten. 
Zusammenfassend zeigen diese Ergebnisse, dass pro-inflammatorische Zytkoine den 
Transport von HDL und apoA-I über die Endothelzellen modulieren. Zudem konnte 
gezeigt werden, dass EL einen HDL Bindungspartner in Endothelzellen darstellt und 
zum transendothelialen Transport von HDL beiträgt. Ausserdem zeigen die Ergebnisse, 
dass das neuartige 3D Modell für die in vitro Untersuchung von Atherosklerose zukünftig 
eine vielversprechende Option darstellen könnte. 
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List of abreviation 
-SMA:    -smooth muscle actin 
-ATPase:   -chain of F0F1 ATPase 
ABCA1:    ATP binding cassett A1 
ABCG1:    ATP binding cassett G1 
Apo:    Apolipoprotein 
CAD:    Cardiovascular disease  
CD31:    Cluster of differentiation 31  
CETP:    Cholesterol ester transfer protein 
EC:     Endothelial cell 
EL:     Endothelial lipase  
eNOS:   Endothelial nitric oxide synthase 
ER:     Endoplasmic reticulum 
Col IV:   Type IV collagen 
GAG:    Glycosaminglycan 
HDL:     High density lipoprotein 
HL:     Hepatic lipase  
HSPG:   Heparan sulfate proteoglycan 
HUVEC:   Human umbilical vein endothelial cells  
Hyp:    Hydroxiproline 
ICAM-I:   Intercellular adhesion molecule-I 
IDL:     Intermediate low density lipoprotein 
IL-1:    Interleukin-1 
IL-6:    Interleukin-6 
LCAT:    Lecithin/cholesterol acyltransferase 
LDL:     Low density lipoprotein  
LDLR:    LDL receptor  
LLR:    LDL like receptor  
LPL:     Lipoprotein lipase 
LXR:    Liver X receptor 
MCP-1   Monocyte chemotactic protein-1 
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MTP:    Microsomal triglyceride transfer protein 
oxLDL:   oxidized LDL 
PLTP:     Phospholipids transfer protein 
SR:    Scavenger receptor 
SR-BI:    Scavenger receptor-BI 
SREBP   Sterol regulatory element-binding protein 
TNF:    Tumour necrosis factor  
UCMFB:   Human umbelical myofibroblast  
VCAM-I:   Vascular cell adhesion-I  
VLDL:    Very low density lipoprotein 
ZO-1:    Tight junction protein 1 
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Vascular physiology  
The cardiovascular system is responsible for the transport of nutriments, gazes and 
blood cells through the entire body. While the heart represents the biomechanical pump 
creating the force to trigger blood flow, blood vessels transport the blood throughout the 
entire body. There are three major types of blood vessels; the arteries, transporting the 
blood away from the heart, the capillaries, enabling the exchanges between blood and 
cells and finally the veins, carrying the blood back to the heart.  
The arteries are of particular interest because they represent the predispose sites of 
atherosclerosis development 1. Arteries are built up of three layers (or tunica); i) the 
tunica intima composed of endothelial cells lining the vessel lumen, ii) the tunica media 
essentially composed of smooth muscle cells and iii) the tunica adventitia consisting of 
connective tissue and anchoring the artery in the surrounding tissue (Fig. 1).   
i) The tunica intima (or intima) is the innermost layer of the artery and limits the 
vessel wall towards the lumen. It is composed of a monolayer of endothelial 
cells demonstrating anti-thrombotic properties as well as semi-permeable 
barrier function by the formation of tight and adherens junctions between the 
cells. Endothelial cells produce in their basolateral side a thin continuous 
extracellular matrix, the basement membrane. This special extracellular matrix 
is essentially composed of type IV collagen, laminin and perlecans 2. In 
addition a layer of elastin, the internal elastic membrane, is separating the 
intima to the media. 
 
ii) The tunica media (or media) is the middle layer and consists primarily of one or 
multiple layers of circumferential arranged smooth muscle cells. Variable 
amounts of elastin, proteoglycans and collagens are located between the 
smooth muscle cells. The external elastic membrane separates the media to 
the adventitia.  
 
iii) The tunica adventitia (or adventitia) forms the outmost connective tissue layer of 
the vessel. It is composed of fibroblasts and longitudinally arranged 
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collagenous tissues anchoring the vessel to the surrounding tissues. In 
addition the adventitia contains small blood vessels (vasa vasorum) supplying 
blood to the vascular wall as well as nerves.  
 
Figure 1: Architecture of a radial artery: The three layer architecture is the adventitia, the 
media with specific staining against smooth muscle cells (-smooth muscle actin) and the intima 
with specific stainings against the basement membrane (type IV collagen) and the endothelial 
cells (CD31). 
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The development of atherosclerosis  
Atherosclerosis is defined by the World Health Organization (WHO) as a complex 
pathological process of medium and large arteries that results in coronary artery disease 
(CAD) and cerebrovascular disease 3. As emphasized by WHO atherosclerosis is an 
important public health problem and remains so far in the westernized countries the 
major cause of death.  
Atherosclerotic lesions are characterized by the accumulation of lipids, fibrous elements 
and cells in the arterial wall over years. In the first decade of life, initial atherosclerotic 
lesions named “fatty streaks” develop. Although they are not clinically relevant they may 
involve into more complicated lesions 4. Atherosclerotic lesions are caused by sustained 
high cholesterol level in particular in low density lipoproteins (LDLs) of the blood plasma 
5. With an increase of LDL plasma concentration, more LDL can insudate and 
accumulate within the arterial wall. The sites exposed to turbulent flow causing shear 
stress of the endothelium are preferential sites to accumulate LDL and further 
atherosclerotic plaque formation 6. Whereas LDL is protected from modification in the 
plasma, it gets prompt for oxidation (oxLDL) within the arterial wall 5,7. In addition to its 
direct cytotoxic properties to endothelial cells 8, oxLDL impairs the endothelial nitric 
oxide synthase (eNOS) expression and activity reducing vascular relaxation 9. Moreover 
it induces the expression of adhesion molecules such as vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins on the 
surface of endothelial cells and it induces secretion of pro-inflammatory cytokines such 
as monocyte chemotactic protein-1 (MCP-1) leading to monocyte recruitment into the 
arterial wall 10.  
Monocytes accumulate within the arterial intima, differentiate into macrophages and take 
up modified LDL via scavenger receptors (SR-A and CD36) 11. These two receptors 
unlike the LDL-receptor (LDLr) are not regulated by the cellular concentration of 
cholesterol. Therefore macrophages accumulate enormous quantities of cholesterol 
esters and differentiate into foam cells (Fig. 2) 5.   
In addition to monocytes, lymphocyte T cells trans-migrate into the arterial wall and 
induce inflammation of the tissue 12. Indeed a general inflammatory state is observed in 
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patients with atherosclerosis and several pro-inflammatory cytokines are detected within 
the plaque, among them the tumor necrosis factor  (TNFα), the interleukins (IL): IL-1β, 
IL-6, IL-8, the interferon  (IFNγ), etc. (review in 13,14). The variety of pro-atherogenic 
molecules including growth factors and cytokines secreted by the macrophage foam 
cells, the T cells and the endothelial cells are responsible of the migration of smooth 
muscle cells into the intima. Smooth muscle cells proliferate and produce extracellular 
matrix protein leading to the thickening of the arterial wall and to the development of a 
fibrous cap covering the lesion area 5. 
	
 
Pathological studies suggest that the blood flow occlusion occurring during myocardial 
infarction or stroke is not caused by severe stenosis but rather by plaque rupture 
resulting in thrombosis. Vulnerable plaques are characterized by thin fibrous caps and 
increased number of immunocytes. Indeed foam cells secrete matrix metalloproteinases 
that destabilize the plaque by degrading extracellular matrix 15. After plaque rupture the 
Figure 2: Initiating events in the development of atherosclerosis lesion. LDL
accumulates in the arterial wall and gets modified inducing endothelial cell activation.
Monocytes and lymphocyte T cells adhere and migrate into the sub-endothelial space.
Monocytes differentiate into macrophage and take up modified LDL via scavenger receptors
leading to foam cell formation. T cells and macrophages foam cells secret inflammatory
cytokines causing chronic inflammation of the tissue. Figure modified from Andersson et al.
131. 
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exposure of the plaque content to the blood induces platelet aggregation and 
coagulation leading to blood clot formation and eventually to blood flow occlusion.  
 
Cholesterol metabolism  
Cholesterol plays a central role in the pathogenesis of atherosclerosis. Francois 
Poulletier de la Salle identified it first in 1769 in its solid form in gallstones however it 
was first named by Eugène Chevreul only in 1815.  The name originates from the Greek 
names chole (bile) and steros (solid) followed by the chemical suffix –ol designating an 
alcohol. Cholesterol belongs to the class of steroid alcohol (sterol) and is a major 
constituent of the cellular plasma membrane in vertebrates where it regulates plasma 
membrane fluidity and permeability. In addition cholesterol is essential in humans for the 
synthesis of bile acids, steroid hormones and vitamins 16.   
Cholesterol results from two sources, the de novo synthesis and the diet. The ratio 
between the de novo synthesis and the diet is about ~70:30. However this ratio probably 
varies considerably between individuals depending on diet and genetic dispositions 17. 
Hepatocytes and enterocytes are the major source of the de novo synthesis even so all 
nucleated cells can synthesize it from the Acyl-CoA via the mevalonate pathway 18. 
Statin drugs designed to reduce plasma cholesterol act on the limiting steps of this 
pathway and inhibit the HMG-CoA reductase to block the conversion of HMG-CoA to 
melavonate. Cholesterol synthesis by the cells is closely regulated by the transcription 
factor sterol-regulating element binding protein (SREBP). SREBP resides in the 
endoplasmic reticulum (ER) and in case of low cholesterol is transported to the Golgi 
where SREBP is further proteolytic processed 19. The N-terminal fragment is then 
imported into the nucleus where it transcribes HMG-CoA reductase and the receptor 
LDLr genes to increase synthesis and up-take of cholesterol by the cell respectively 20. 
Sufficient amounts of cellular sterols inhibit the ER-Golgi transport of SREBPs by 
interaction of the two chaperons SREBP cleavage activating protein (SCAP) and insulin 
induced gene (INSIG). Indeed when sterols bind to SCAP and INSIG the two 
chaperones bind together and trap SREBP in the ER 21. Dietary cholesterol is taken up 
by the enterocytes and further transported to the liver.  
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Lipoprotein metabolism  
Since cholesterol is a hydrophobic molecule, enterocytes and hepatocytes pack it into 
lipoproteins for the transport in blood. Lipoproteins are complex particles of lipids bound 
to proteins characterized by a shelf of phospholipids and cholesterol with at least one 
apolipoprotein and a core with triglyceride and cholesterol esters. Lipoproteins are 
differentiated according to their density (table 1). The density of the lipoproteins is 
related to the ratio between lipids and apolipoproteins. The less proteins the lower is the 
density.  
Table 1: Lipoproteins classification  
NAME Density (g/ml) Diameter (nm) % proteins Apolipoproteins 
Chylomicron < 0.95 100-1000 < 2 B48, A-I, A-II, E, C-I C-II C-III, H 
VLDL 0.95-1-006 30-80 10 B100, C-I, C-II, C-III, E 
IDL 1.006-1.019 25-50 18 B100, C-II, C-III, E 
LDL 1.019-1.063 18-28 25 B100 
HDL > 1.063 5-15 33 A-I, A-II, A-IV, C-I, C-II, C-III, C-IV, D, E, F, H, J, L-I, M 
 
Dietary lipids transport 
Dietary lipids are absorbed by the small intestine particularly by the enterocytes after 
they were hydrolyzed by lipases. The absorbed lipolytic products -monoacylglycerol, free 
cholesterol, lysophospholipids and fatty acids- are resynthesized to 
phosphatidylcholines, triacylglycerol and cholesteryl esters and then assembled with 
apoB48 to chylomicrons that are further processed to the Golgi and secreted into the 
lymph 22,23. In the circulation, chylomicrons exchange apolipoproteins (apoA-I, apoE and 
apoC-I) with the high density lipoprotein (HDL). In the capillaries of adipose tissue, 
skeletal and cardiac muscles, triacylglycerol of chylomicrons are hydrolyzed by 
lipoprotein lipase (LPL) to provide fatty acids and glycerol to adipocytes and myocytes.  
During this process chylomicrons size is reduced to become chylomicron remnants that 
are absorbed and further degraded by the liver through apoE receptor (apoEr) (Fig 3).  
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De novo lipids transport  
The liver synthesizes triglycerides and cholesterol and packages them into the very low 
density lipoprotein (VLDL). The assembly of the VLDL begins by the lipidation of 
ApoB100 in the ER by the microsomal triglyceride transfer protein (MTP) and its 
translocation from the ER lumen to the Golgi complex. MTP represent the limiting step in 
the formation of VLDL in the liver and chylomicron in the intestine, without this chaperon 
processing apoB100 is blocked and degraded 24. Nascent VLDL is released into the blood 
stream and maturates by exchanging cholesterol esters and triglycerides with HDL via 
the cholesteryl ester transfer protein (CETP).  
VLDL triglycerides are hydrolyzed in the adipose tissues and musculature by the 
lipoprotein lipase (LPL) and converted into intermediated low density lipoprotein (IDL). 
IDLs are either taken up by the hepatic LDL receptor-related protein (LRP) or undergo 
hydrolysis of residual triglycerides by hepatic lipase (HL) (Fig 3).  
The resulting LDL is composed of a single apoB100 and in contrary to the VLDL, is a 
cholesterol ester rich particle. LDL is cleared from the plasma via the LDLr mostly in the 
liver.  
The liver and the intestine produce one additional class of lipoproteins, HDL. ApoA-I, the 
main protein of HDL, is secreted by hepatocytes and the enterocytes in a ratio of 70:30 
respectively. After secretion from hepatocytes and enterocytes, apoA-I acquires 
immediately phospholipids and cholesterol from the plasma mediated by the membrane 
ATP binding cassette transporter (ABC)A1 25,26.  The resulting nascent HDL acquires 
additional cholesterol and phospholipids via ABCA1 and ABCG1 mediated efflux. 
Unesterified cholesterol transferred to HDL are esterified by the lecithin/cholesterol 
acyltransferase (LCAT). The cholesterol esters accumulate in the core and make HDL 
spherical. These particles are modified by a variety of enzymes. CETP swaps 
cholesterol esters from HDL for triglycerides from VLDL and LDL whereas the 
phospholipid transfer protein (PLTP) exchanges phospholipids and free cholesterol 27. In 
addition HL and endothelial lipase (EL) remodel HDL by hydrolyzing triglycerides and 
phospholipids. HDL cholesterol is delivered back to the liver via interaction with SR-BI 
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which results in selective uptake of lipids or by holoparticle uptake through an as yet 
unknown pathway which is activated by ectopic -ATPase (Fig. 3).  
 
Figure 3: Lipoprotein metabolism. The intestine absorbs dietary lipids and packages them 
with apoB48 into chylomicrons, which are transported to peripheral tissues through the blood and 
then they are hydrolyzed by LPL. The chylomicron remnants are subsequently taken up by the 
liver by apoE receptor. De novo synthesized lipids are loaded onto apoB100 particles to form 
VLDL which undergo lipolysis by LPL to form IDL and further LDL particles. IDL and LDL deliver 
cholesterol and phospholipids mainly to the liver through binding to the LDLr or LRP receptor. In 
atherosclerotic lesions LDL is modified and taken up through scavenger receptors which are not 
regulated by cellular cholesterol content. HDL is generated by the liver and intestine through the 
secretion of lipid-free apoA-I. ApoA-I then recruits cholesterol from these organs through the 
actions of ABCA1, to form discoidal HDL. In the peripheral tissues, lipid-free apoA-I and 
discoidal HDL promote the efflux of cholesterol through ABCA1 and ABCG1 respectively. The 
unesterified cholesterol in HDL is esterified to cholesteryl ester by LCAT, creating mature HDL. 
The HDL cholesterol is returned to the liver both directly, through selective uptake by SR-BI, and 
indirectly, by transfer to LDL through CETP. The lipid content of HDL is altered by the enzymes 
HL and EL and by the transfer proteins CETP and PLTP, affecting HDL catabolism (adapted 
from Rader et al.  28). 
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High density lipoprotein properties 
HDL, often referred as the “good cholesterol”, is an heterogeneous class of lipoproteins, 
which are separated to distinct subclasses by different shapes, densities, sizes, lipid and 
protein contents 29. HDL is produced as a small and lipid-poor (mainly phospholipids and 
cholesterol) discoidal shaped particle. LCAT activity converts HDL into spherical particle 
with a cholesteryl ester core, the predominating form in the plasma. Furthermore density 
classification differentiates two classes of HDL; a larger lipid-rich HDL2 (1.063-1.125 
g/ml) and a denser protein-rich HDL3 (1.125-1.21 g/ml) 30. A further classification based 
on the size further categorized HDL2 and HDL3 in five subpopulations of decreasing size 
from 10.6 to 7.6 nm: HDL2b, HDL2a, HDL3a, HDL3b and HDL3c 30.   
Lipidome and proteome are also variable among the HDL particles. Currently lipidome 
analysis has revealed more than 200 individual lipid species in normolipidemic plasma, 
including cholesterol, triglycerides and phospholipids there are sphingolipids, 
phosphatidylcholines, ceramides, etc.31. In addition over 200 individual proteins have 
been identified and in these 85 were found by at least three independent laboratories 
and represent the best current estimation of the HDL proteome 32. Interestingly recent 
finding revealed differences in the HDL proteome between healthy subjects and CAD 
patients some of them changing the properties of HDL 33. Indeed HDL possess several 
anti-atherogenic properties inducing the improvement of vasculature function, the 
inhibition of vascular inflammation, the prevention of lipid oxidation, the inhibition of cell 
apoptosis and platelet aggregation as well as the stimulation of endothelial repair. 
Indeed the blood concentration of HDL-cholesterol is inversely correlated with the risk of 
cardiac events and strokes 34. HDL is believed to remove cholesterol out of the 
macrophage foam cells in the atherosclerotic plaque and carried it back to the liver for 
disposal into the bile in a process named as reverse cholesterol transport (RCT) 35. 
Cholesterol efflux from the macrophage foam cells to HDL, lipid-free or lipid-poor apoA-I 
was initially believed to be mediated by passive diffusion 36. It is now clear that 
cholesterol efflux is facilitated by active transporters namely ABCA1 and ABCG1. 
ABCA1 mediates cholesterol efflux to lipid-free or lipid-poor apoA-I whereas ABCG1 
mediates it to mature HDL 37.  
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Scavenger receptor BI  
SR-BI is a 82-kDa membrane glycoprotein containing a large extracellular and two trans-
membrane domains with a short cytoplasmic amino- and carboxyl-terminal domain 38.  
SR-BI was initially found in the liver but is also expressed in other tissues and cells types 
such as macrophages and endothelial cells. SR-BI binds HDL with high affinity but also 
nevertheless other lipoproteins (LDL, oxLDL, etc.) 39. The binding of HDL to SR-BI 
facilitates the uptake of cholesteryl esters into hepatocytes and steroidogenic cells in a 
process known as selective uptake 40. The selective uptake to hepatocytes plays a 
central role in the RCT by removing cholesterol from HDL for excretion into the bile.  
Several lines of evidence suggest the central role of SR-BI in atherosclerosis. SR-BI-/- 
mice cross with atherosclerotic background (LDLR-/- or apoE-/-) develop more 
atherosclerotic lesions 41. Whereas mice with specific hepatic SR-BI overexpression 
demonstrate a decrease in atherosclerotic lesions 42. Furthermore patients with a SR-BI 
mutation demonstrate an increased risk of cardiovascular events 43,44. The role of SR-BI 
in cholesterol efflux has been intensively studied and demonstrated a minor role of SR-
BI in promoting direct cholesterol efflux from macrophage foam cells in comparison to 
ABCA1 and ABCG1 45. Nevertheless SR-BI-/- bone marrow transplantation in apoE-/-  
mice demonstrated an increase of atherosclerosis lesions suggesting a protective role of 
macrophage SR-BI independent of cholesterol efflux 46. 
In addition to its pivotal role in RCT, SR-BI regulates multiple processes in vascular cells 
important for vessel physiology. In endothelial cells the binding of HDL to SR-BI induces 
the activation of eNOS and the subsequent production of nitric oxide causing blood 
vessel relaxation 47. The signaling cascade stimulating eNOS activity after HDL/SR-BI 
interaction has been identified and requires the capacity of SR-BI for cholesterol efflux, 
the C-terminal trans-membrane domain (CTTM) and the C-terminal cytoplasmic domain 
bound to the PDZ interacting protein. After cholesterol efflux, CTTM acts as a 
cholesterol sensor and PDZK1 initiates a kinase cascade involving SRC kinase, which 
activates Akt which phosphorylates eNOS at position 1177 48.  
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SR/BI-HDL interaction also stimulates endothelial cell migration as well as endothelial 
repair and prevents of platelet activation and aggregation 49,50.  
In conclusion SR-BI is both an important regulator of HDL cholesterol concentration in 
the blood and a multifunctional signaling HDL receptor. 
 
Endothelial lipase 
Endothelial lipase was first described in 1999 by two independent groups and is a 
phospholipase that belongs to the triacylglycerol lipase family including also LPL and HL 
51,52. EL is a 68-kDa glycoprotein sharing 44% and 41% amino acids sequence 
homology with HL and LPL, respectively. Nevertheless the lipolytic site largely differs 
between EL, HL and LPL. EL is mainly synthesized by vascular endothelial cells which 
gave its name however also other cells types such as macrophages and smooth muscle 
cells express it too 53. EL is secreted into the extracellular space, where it binds to the 
cell surface heparan sulfates proteoglycans (HSPG) and exerts its lipolytic action 54. 
Griffon et al. reported that EL forms a head-to-tail homodimer on the HSPG 55.  
In contrast to LPL, which has mainly triglyceride lipase activity, and HL, which exhibits 
both triglyceride and phospholipase lipase activities, EL has a primarily sn-1-
phospholipase activity and is a negative regulator of HDL cholesterol level. Over-
expression of EL in mice demonstrated a marked decrease of HDL cholesterol and 
apoA-I concentration in the plasma due to an increase in the catabolic rate of HDL 56–58. 
Concomitant with these findings, EL-/- mice or mice after pharmacological inhibition of EL 
results in bigger HDL particle size and an increase of HDL-cholesterol, apoA-I and 
phospholipid concentration in the plasma due to a decrease of the HDL catabolic rate 
57,59,60. 
Several rodent studies analyzed the role of EL in RCT but revealed contradictory results. 
Indeed Yancey et al. showed that mice overexpressing EL have smaller HDL particles 
and an increase of macrophage cholesterol efflux via ABCA1 but not ABCG1 61. In 
addition in vitro experiment showed that in macrophages, EL facilitates cholesterol efflux 
to apoA-I through its bridging function and lipolytic activity 62. By contrast Brown et al. 
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revealed that the HDL from EL-/- mice increase cholesterol efflux compared to HDL from 
the wild type animals 60.  
Although the role of EL in macrophage cholesterol efflux remains so far unclear it is 
consistently reported that EL increases the hepatic cholesterol uptake. Strauss et al. 
reported that EL mediates HDL binding and uptake in vitro via its lipolytic and bridging 
functions in hepatocytes and promotes the selective uptake of cholesterol esters 63. 
Brown et al. reported that selective uptake is diminished in EL-/- mice 60. Additionally the 
selective cholesterol uptake is enhanced in EL overexpressing mice dependently of SR-
BI expression 56,64. These findings indicate that the selective cholesterol uptake by SR-
BI requires remodeling of HDL by EL.  
 
The role of EL in the pathogenesis of atherosclerosis is not yet clear. Hirita and 
colleagues revealed that EL-/- mice have reduced atherosclerotic lesion development, 
whereas mice overexpressing EL have larger lesions 57,65. Conversely Ko et al. reported 
no change in atherosclerotic plaque formation in EL-/- mice with apoE-/- and LDLR-/- 
background 66.  
Several point mutations have been described in humans. The two low frequency 
mutations A396S and G26S impair lipolytic function and lower EL concentration 
respectively and are associated with a high HDL concentration in the plasma 67,68. 
Another more common mutation T111I demonstrated no change in lipolytic activity 
compared to wild type EL and failed to correlate with HDL-cholesterol plasma 
concentration in a meta-analysis of five cohort studies 67. The association of T111I with 
atherosclerosis is also controversial. Whereas two studies reported a decrease of CAD 
risk particularly in Chinese population 69,70, larger studies on Caucasian population 
revealed no association between the point mutation T111I and CAD 71–74. Finally Cai et 
al. revealed that the point mutation A384C increased HDL and apoA-I blood 
concentration and reduced CAD risk in Chinese population 75.    
In conclusion EL appears to have a central role in HDL metabolism. However its exact 
role in atherosclerosis genesis has to be further investigated. 
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ATP binding cassette  
Some members of the ATP binding cassette (ABC) superfamily are regulating different 
steps in cellular cholesterol metabolism. Their functions are opposed to the LDLr and 
allow cells to export cholesterol and phospholipids. In humans the ABC superfamily 
comprises 48 transporters divided into 7 subfamilies from A to G 76. Structurally the ABC 
transporters are distinguished into full transporters made of two units covalently bound 
and half transporters of single units forming of homo- or heterodimers. Each units of an 
ABC transporter is composed of six-trans-membrane -helixes and an intracellular 
amino-terminal ATP binding domain also known as nucleotide binding domain (NBD). 
Among the full superfamily of ABC transporters at least four are believed to be involved 
in lipoprotein metabolism namely ABCG1, ABCG4, ABCG8 and ABCA1 77. As floppases 
they transport the lipids from the inner to the outer leaflet of membranes for excretion 78.  
The role of ABCG1 and ABCA1 on HDL metabolism is further discussed in the following 
paragraphs. 
 
ABCA1 
ABCA1 is a full trans-membrane transporter of 240-kDA comprising two analogue 
structural units 79. ABCA1 is predominantly expressed in hepatocytes, macrophages and 
astrocytes but other cells types such endothelial cells also express it.  
The importance of ABCA1 in cholesterol metabolism was first highlighted in patients 
suffering from Tangier disease. These patients are characterized by a dramatic 
reduction of HDL particle concentration in the plasma as well as cholesterol ester 
deposition in various tissues specially the tonsils. An increase of lipid-free apoA-I 
catabolism causes the reduction of HDL-cholesterol concentration. Tangier disease is 
caused by different mutations in the ABCA1 gene preventing correct protein folding or 
expression in the hepatocytes 80. ABCA1-/- mice show a similar phenotype as Tangier 
disease patients. Mice overexpressing ABCA1 have an elevated HDL concentration 81.  
ABCA1 expression is enhanced by a high cholesterol content of the cells and is 
regulated by the nuclear receptor liver X receptor (LXR) 82. ABCA1 is responsible of the 
transport of phospholipids and cholesterol to the external leaflet of the plasma 
	 26
membrane where it is accessible to lipid-free or lipid-poor apoA-I but not to mature HDL. 
This process is best explained in hepatocytes and cholesterol loaded macrophages. Our 
group recently demonstrated that in endothelial cells ABCA1 also lipidates apoA-I 83.  
ABCA1 is found in the intracellular compartment and on the cell surface and the location 
for apoA-I lipidation remains controversial. A first theory suggests that ABCA1 
translocates cholesterol and phospholipids from the inner to the outer membrane leaflet 
by forming a transport chamber with its two trans-membrane domain. Cholesterol and 
phospholipids then form a lipid domain on the plasma membrane accessible for 
solubilisation by apoA-I 84,85. A second model call the retro-endocytosis theory suggests 
that apoA-I binds to ABCA1 and the complex is internalized to intracellular lipids 
deposits where lipidation occurs before exocytosis 86,87. Newer studies by Chen et al. 
revealed evidences that both mechanisms take place in the same cell 88.  
The role of ABCA1 in the development of atherosclerosis has been intensively studied. 
The association of Tangier disease with CAD has been observed in some patients but 
not in other 89–91. Animal studies revealed also controversial results. Aiello et al. 
demonstrated that ABCA1-/- mice or mice with ABCA1-/- bone marrow transplantation 
have increase atherosclerotic lesions 92. However several studies reported that despite a 
marked changes in the plasma lipoprotein profiles and macrophage efflux, ABCA1-/- 
mice do not have increased atherosclerosis 81,93,94.  In addition, several studies with 
mice overexpressing ABCA1 demonstrated a reduction of atherosclerosis genesis 95–97. 
Whereas Joyce et al. reported a significant increase in atherosclerosis in mice 
overexpressing ABCA1 98. The combine results of studies in Tangier disease patients, 
ABCA1-/- mice and mice overexpressing ABCA1 indicate that the effects of ABCA1 on 
genesis of atherosclerosis are complex and need further investigations. 
Taking all together ABCA1 appears to play a central role in HDL cholesterol metabolism. 
However the exact mechanisms of apoA-I lipidation and cholesterol efflux remain so far 
unclear.   
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ABCG1 
ABCG1 is a half transporter believed to be functional either as homo- or heterodimers 
with ABCG4 99. ABCG1 is predominantly expressed in hepatocytes and macrophages 
but also in other cells types.  
Venkateswaran et al. revealed an induction of ABCG1 by the cholesterol signaling LXR-
dependent nuclear receptor system and was the first to suggest its role in cholesterol 
metabolism 100. In macrophages filled with cholesterol, LXR stimulates ABCG1 
expression and its translocation from the intracellular compartments to the cell surface 
101. Suppression of ABCG1 in macrophages reduces the cholesterol efflux to HDL and 
further confirmed its role in cholesterol metabolism 102. In addition ABCG1-/- mice have a 
marked accumulation of lipids in the tissues 103.  
In contrast to ABCA1, which transports both phospholipids and cholesterol, ABCG1 is 
mainly a cholesterol transporter. After transporting cholesterol to the cell surface ABCG1 
mediates cholesterol efflux from the cells to HDL but not to lipid-free apoA-I 85. To 
corroborate the importance of ABCG1 in cholesterol metabolism Wiersma et al. revealed 
that ABCG1-/- mice have a decreased HDL level in the plasma and an increased 
cholesterol excretion into the bile 104. However Kennedy et al. revealed no change in 
plasma lipids in ABCG1-/- mice but an accumulation in the tissues 103.    
Whereas its role in macrophage cholesterol efflux is well documented, the function of 
ABCG1 in the development of atherosclerosis remains poorly understood. Several 
independent studies revealed an anti-atherosclerotic effect of ABCG1. Indeed ABCG1-/- 
mice or mice after ABCG1-/- bone marrow transplantation fed with high fat diet revealed 
an increase of atherosclerotic plaque development 105–108. Nevertheless other studies 
demonstrated that ABCG1-/- mice or mice after ABCG1-/- bone marrow transplantation 
have reduced atherosclerotic lesions either in apoE-/- or LDLR-/- background 109–111. In a 
more recent manuscript, Meurs et al. suggest that the differences of these studies may 
be due to the stage of the atherosclerotic lesions 112. Moreover ABCG1 overexpression 
in the arterial wall reduces atherosclerotic lesion in rabbits 113. 
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In summary ABCG1 is an important key player in cholesterol efflux and HDL 
metabolism, however its exact role on atherosclerosis development needs to be further 
investigated.  
 
Ectopic -chain of the F0F1-ATPase 
Martinez et al. identified for the first time in 2003 that the ectopic F0F1-ATPase binds 
apoA-I in hepatocytes 114. Our group recently demonstrated that -chain of the F0F1-
ATPase binds apoA-I in endothelial cells 115. 
The F0F1-ATPase is an enzymatic complex present on the membrane of prokaryotes, 
chloroplasts and mitochondria involves in the synthesis or hydrolysis of ATP. The F0F1-
ATPase is composed of two units; the trans-membrane F0 domain, which function as a 
proton channel 116 and the peripheral F1 domain, which carries the catalytic site for ATP 
synthesis or hydrolysis 117.  Interestingly the F0F1-ATPase was found on the plasma 
membrane of endothelial cells, hepatocytes and tumor cells by cell surface biotinylation 
and confocal microscopy 114,118,119. On the plasma membrane the F1 domain is 
extracellular and fully functional. Although the mechanisms leading to the ectopic 
localization remains unknown, Wang et al. revealed that cholesterol loading induces its 
ectopic localization suggesting a possible role in cholesterol metabolism 120.  
In addition to its mitochondrial function in ATP metabolism, the ectopic ATPase was 
reported to be a receptor for several ligands such as peptides, angiostatin and apoA-I 
121. Moreover in hepatocytes and endothelial cells apoA-I bound to the ectopic ATPase 
triggers HDL endocytosis 114,115. Indeed upon binding of apoA-I, the F0F1-ATPase 
hydrolyses ATP to ADP, which activates the purinergic receptor P2Y13 in hepatocytes 
and P2Y12 in endothelial cells respectively. Activation of these receptors leads to G 
protein activations and increases HDL uptake 114,115.  
In summary the -chain of the F0F1-ATPase appears to plays a role in HDL endocytosis 
by endothelial cells and hepatocytes however its role in cholesterol metabolism and 
atherosclerosis genesis needs further investigation.   
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Trans-endothelial transport of HDL and apoA-I 
Taking all together, RCT by HDL or by lipid-free apoA-I are both crucial in preventing 
atherosclerosis. However cholesterol efflux is taking place in the arterial wall therefore 
HDL and lipid-free apoA-I has to pass the endothelium barrier to get access to the 
cholesterol load macrophages. Several translocation routes are theoretically possible, 
diffusion through lesions, intercellular, active paracellular or intracellular transports.  
Endothelial cell-to-cell junctions are characterized by the presence of tight junctions, 
adherens junctions and gap junctions and their main function is to limit paracellular 
permeability 122. Therefore paracellular transport requires the opening of these junctions. 
This process is highly regulated by specific extrinsic and intrinsic signaling pathways and 
requires actin cytoskeleton remodeling 123.  Interestingly sphingosine-1-phosphate (S1P) 
stabilizes the integrity of endothelial barrier 123,124. Since HDL carries more than 50 % of 
S1P 125 and it is a regulator of endothelium integrity 126, one may speculate that HDL is 
not transported paracellularly but rather intracellulary.  
The intracellular transport or transcytosis is characterized by endocytosis, vesicular 
transport and exocytosis. This happens either receptor-independent (fluid phase) or 
receptor-mediated involving either clathrin or caveolin coated pits 123.  Chao et al. 
reported that fluorescent- and gold-labeled HDL appears to colocalize with caveolin in 
aortic endothelial cells 127. In addition internalized HDL is found in vesicles in endothelial 
cells 128. Our group demonstrated with aortic endothelial cells cultivated on a transwell 
system that HDL or lipid free apoA-I are transported through a confluent monolayer in a 
temperature dependent process 128,129. Furthermore we found that ABCG1, SR-BI are 
involved in the transport of HDL while lipid-free apoA-I translocation depends on ABCA1 
and the ectopic -ATPase  (Fig. 4) 115,128,130.  
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Figure 4: Trans-endothelial transport of HDL and apoA-I. HDL binds to ECs and is 
internalized dependently of SR-BI and ABCG1. Lipids-free apoA-I binds to ABCA1 and gets 
lapidated. It is further internalized by ABCA1 independent mechanisms. In addition lipid-free 
apoA-I binds to the ectopic -ATPase and signals via P2Y receptor to induce internalization of 
lipidated apoA-I and HDL 115. 
 
Aim of the present study 
Our group intensively studied the trans-endothelial transport of HDL and apoA-I, 
however the inflammatory state of the atherosclerotic plaques may influence the 
transport through the endothelium. Therefore the aim of the present study is to analyze 
the transport of HDL and apoA-I through a monolayer of endothelial cells in the 
presence of inflammatory cytokines. 
In contrast to the in vitro model, the native artery is a complex tissue composed of 
smooth muscle cells, endothelial cells and extra-cellular matrix. Therefore a second aim 
is to bioengineer an artery equivalent model. With this native like tissue-engineered 
artery model there will be many studies possible as the development of atherosclerotic 
plaque as well as the trans-endothelial transport of HDL under flow conditions ex vivo.  
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Abstract 
Objective: In the reverse cholesterol transport pathway, high-density lipoprotein (HDL) 
passes the endothelial cell barrier by mechanisms involving the scavenger receptor 
(SR)-BI and the ATP binding cassette (ATP) G1. However little is known on how 
inflammation influences this trans-endothelium transport. We hypothesize that 
interleukin (IL)-6 influences the trans-endothelial transport of HDL.  
Approach and results: Upon stimulation with IL-6 cultivated primary endothelial cells 
showed increased binding and transport of 125I-HDL without changing the expression of 
SR-BI and ABCG1. Therefore we analyzed the involvement of endothelial lipase (EL), a 
known HDL binding protein expressed by endothelial cells. Here we show an increase of 
EL expression after IL-6 stimulation. Moreover using pharmacological inhibitors or RNA 
interference against EL we demonstrated its participation in HDL binding and transport 
through the endothelium. EL was also found responsible for the reduction of HDL-
particle size occurring during the specific transport through a monolayer of endothelial 
cells. Finally, pharmacological inhibition of EL after IL-6 stimulation reversed the 
inducing effect of IL-6 on HDL binding and transport.   
Conclusion: IL-6 stimulates the translocation of HDL through the endothelium, the first 
step in reverse cholesterol transport pathway.  
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Introduction 
Atherosclerosis is a chronic disease characterized by lipid retention and inflammation in 
the arterial wall. Many studies revealed that the cholesterol concentration of plasma high 
density lipoproteins (HDL) is inversely correlated with the risk of coronary artery disease 
events 1. The cardio protective role of HDL is, in part, related to its ability to remove the 
cholesterol from the macrophage foam cells in the arterial wall and carry it to the liver for 
excretion into the bile 2. An early step in the reverse cholesterol transport is the transfer 
of cholesterol from the macrophages to the HDLs. Importantly the loading of cholesterol 
is not taking place in the plasma but in the arterial intima 2. Consequently HDL has to 
cross the endothelium barrier to get access to the cholesterol-loaded macrophages. We 
previously demonstrated that endothelial cells bind, internalize and transcytose HDL in a 
saturable and temperature dependent manner. Using siRNA and pharmacological 
interferences we demonstrated that endothelial cells bind and transport HDL by distinct 
specific mechanisms involving the scavenger receptor (SR)BI and the ATP binding 
cassette transporter (ABC) G1 but not ABCA1 3.  
In inflammatory diseases such as atherosclerosis, many (inflammatory) cytokines have 
been demonstrated to be elevated in patient plasma among them the tumor necrosis 
factor  (TNF), the interleukins (IL) -1 and IL-6 4. Moreover Hingorani and Casas as 
well as Sarwar et al. recently demonstrated a correlation between the IL-6 receptor 
pathway and atherosclerosis 5,6. IL-6 has been also demonstrated to increase the 
cholesterol efflux to HDL in macrophages 7. Consequently we hypothesized that IL-6 
may modulate the trans-endothelial transport of HDL. Indeed, we provide evidences that 
IL-6 enhances binding and transport of HDL in an SR-BI and ABCG1 independent way. 
This observation raised the possibility that an additional protein is involved in the 
binding, internalization and transport of HDL through endothelial cells. In a candidate 
based approach we investigated if endothelial lipase (EL) is involved. Vascular 
endothelial cells express and secrete EL a glycoprotein of 68-kDA which binds to the 
cellular proteoglycans where it exerts its action, EL binds HDL, hydrolysis HDL-
phospholipids at the sn-1 position and is a regulator of the plasma HDL cholesterol level 
8,9. Moreover, several groups demonstrated a positive correlation between the 
expression of EL and inflammation in vitro as well as in vivo 10–13. In this study, we 
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provide evidences that EL participates in HDL binding, cell association and transport. In 
addition IL-6 induces EL expression in endothelial cells and consequently the HDL 
binding and transport is enhanced. 
 
Material and Methods  
Endothelial binding, cell association and transport of HDL 
The methods for the isolation and radiolabeling of HDL, the cultivation of bovine aortic 
endothelial cells as well as the quantification of endothelial binding, association, 
internalization, and transport of HDL have been described previously 3,14,15. In brief, 
endothelial cells were incubated with 10 g/ml of 125I-HDL without (total) or with  a 40 
folds excess of non-labeled HDL (non-specific) for 1 hour at 4 °C for the cell binding and 
37 °C for the cell association and transport. Specific binding/association/transport was 
calculated by subtracting the non-specific binding/association/transport to the total 
binding/association/transport. All experiment were done in at least triplicate. 
Pharmacological treatment and inhibitors  
Endothelial cells were incubated with IL-6 (Preprotech, USA) at a final concentration of 
10 ng/ml for 24 h in DMEM containing 0.2% BSA prior the assay. To test the 
involvement of EL in HDL cell binding, association and transport endothelial cells were 
incubated with heparin (Sigma) at a final concentration 100 g/ml of or with heparinase 
III (Sigma) at a final concentration of 0.2 U/ml for both 30min priors the assay. THL 
(Sigma) was added to the cells at a final concentration of 25 µM in DMEM hepes 
containing 0.2% BSA 30 min prior adding 125I-HDL. 
SiRNA transfection  
Endothelial cells were transfected when 80% to 90% confluent. Sixty-seven nmol/L 
BLOCK-iTTM fluorescent oligo and 100 nmol/L siRNA against EL (GCA AGC AUC CUC 
CUU GCU UTT, GCU CGG UGA GUU CGA CAA ATT or AUC CAU GUC UUC AGC 
UAC ATT) (Microsynth, Switzerland), SR-BI (TCG TCA TGC CCA ACA TCC TGG TCT 
T) (Invitrogen) or not coding siRNA were transfected with Lipofectamine 2000 in 
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OPTIMEM (Invitrogen) according to the manufacturer's protocol. Six hours after 
transfection, the medium was replaced by DMEM 5% FCS. Binding, cell association, 
transport and gel filtration assays were conducted between 60 and 72 hours after the 
transfection. 
Quantitative real time PCR 
Total RNA was isolated from the cells using RNA Bee (Ambio, Switzerland) according to 
the manufacturer’s instruction. Genomic DNA was removed by digestion with DNase 
(Roche). Reverse transcription was performed using ReverstAid H Minus (Fermentas, 
Thermo Scientific) and following the standard procedure as defined by the manufacturer. 
Quantitative PCR was done with LightCycler FastStart DNA Master SYBR Green I 
(Roche). Genetic specific primers were used as followed: ABCG1 (for: GAG GAA GAA 
AGG ATA CAA GAC C; rev: GTC AGT ATC TCC TTG ACC ATT TCC), SR-BI (for: GGA 
ATC CCC ATG AAC TG; rev: CTT GGG AGC TGA TGT CAT C) and EL (for: CAC CAA 
CAC CTT CCT GGT CT; rev: TTT TTC ATC CTC CAG CCA TC) and compared to actin 
(for: TGC CCT GGC ACC CAG CAC AA; rev: AGG TGG ACA GCG AGG CCA GG). 
Conventional PCR was carried out using following primers: GAPDH (for: CCC ATG TTC 
GTC ATG GGT GT; rev: TGG TCA TGA GTC CTT CCA GCA TA). 
Western Blotting 
Endothelial cells were lysed in RIPA buffer (10 mmol/L Tris pH 7.4, 150 mmol/L NaCl. 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS, complete EDTA (Roche)). Equal 
amounts of total protein were separated on a SDS-PAGE and trans blotted onto a PDVF 
membrane (GE Healthcare). The expression of ABCG1 (anti ABCG1 E20 Santa Cruz), 
SR-BI (anti SR-BI E4 Novus or anti SR-BI EP1556Y ABCAM) and EL (anti EL NB 400-
118 Novus) were evaluated and compared to the expression of actin (anti actin AC-15, 
Sigma). Intensity of the blot was quantified using Image J. 
Gel filtration chromatography  
The size of HDL before and after transport studies through cells previously treated with 
THL or RNA interference against EL and SR-BI was analyzed by gel filtration 
chromatography as previously described 3.   
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Lipase activity assay 
The lipase activity of endothelial cells was measured using PED-A1 (Invitrogen) 
following the manufacturer instruction as previously described by Darrow, A. et al. with 
the following modifications 9. Endothelial cells (2.5 E106) after IL-6 or THL incubation 
were treated with heparinase as described previously in 0.9% NaCl. Supernatant was 
collected and concentrated 10 folds with 30K Amicon Ultra concentrator (Millipor) before 
incubating with PED-A1 for 2 hours.  
Statistical analysis 
The data for all experiments were analyzed using GraphPad Prism 5 software program. 
Comparisons between groups were performed using t-test or ANOVA. Experiments 
were routinely performed in triplicate. The data have been obtained from at least 3 
different experiments and are graphically represent as mean ± standard deviation, if not 
indicated otherwise. n.s. not significant; * P<0.05; ** P<0.001; *** P<0.0001 
 
Results 
IL-6 induces HDL binding, cell association and transport  
To investigate whether the interaction of HDL with endothelial cells is changed by the 
inflammatory cytokine IL-6, we stimulated aortic endothelial cells with IL-6. The 
interaction of HDL with the endothelial cells was characterized as binding at 4 °C, cell 
association and transport at 37 °C. After 24 hours of IL-6 stimulation, specific binding 
was induced by 200% compared to not stimulated cells (Fig. 1A). Conversely the 
specific cellular associated HDL and the transported HDL were also induced by 144% 
and 178% respectively (Fig. 1B and C). Moreover to rule out that the induction of HDL 
transport was due to permeability changes after IL-6 stimulation, the integrity of the 
endothelial cells monolayer was assessed by analyzing the permeability with 3H-inulin. 
The tracer was added to the apical chamber and the radioactivity in the basolateral 
chamber was counted. The permeability coefficient was not changed after IL-6 
stimulation compared to the control, namely 1.756 E10-5  0.156 E10-5 cm/s and 1.863 
E10-5  0.208 E10-5 cm/s (Fig. 1D) over a time period of 1 hour.  
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Figure 1: Influence of IL-6 on endothelial binding at 4°C (A), cell association at 37°C (B), 
and transport of HDL (C) as well as permeability (D). ECs were stimulated with IL-6 (10 
ng/ml) for 24 hours prior the assays. Binding (A) was measured by incubating the cells with 10 
g/ml 125I-HDL at 4 °C. To analyze the association (B) and transport (C) ECs were cultivated for 
24 hours on insert before IL-6 stimulation then 125I-HDL was added to the apical compartment. 
After one hour at 37 °C cells were lysed and specific activity was counted to obtain cell 
association (B). Medium of the basal compartment was harvested and specific activity was 
monitored to obtain the transport (C). The permeability of the cell monolayer to inulin was 
determined (D). The results are represented as mean  SD of at least 3 individual experiments 
made of triplicate. 
 
Previously, we demonstrated that ABCG1 and SR-BI modulate the endothelial cell 
interaction with HDL. Therefore, we analyzed the mRNA level and protein expression of 
ABCG1 and SR-BI after IL-6 stimulation. Interestingly, real time RT-PCR analysis did not 
demonstrate any changes in the expression levels of ABCG1 and SR-BI after IL-6 
stimulation, namely 1.23  0.33 fold for SR-BI and 1.10  0.49 fold for ABCG1 relative 
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expression compared to not stimulated cells set to 1 (Fig. 2A & B). Moreover western 
blot analyses of the protein expression levels of ABCG1 and SR-BI after stimulation 
were not significantly changed (respectively 1.07  0.44 fold and 0.89 0.37 fold) (Fig. 
2C & D). These results indicated that enhanced cell binding, association and transport of 
HDL after IL-6 stimulation is independent of SR-BI and ABCG1.  
 
Figure 2: mRNA and protein expression of SR-BI (A, C) and ABCG1 (B, D) after IL-6 
stimulation (10 ng/ml; 24 h). The mRNA expressions of SR-BI (A) or ABCG1 (B) were 
quantified using real time RT-PCR and compared to the expression of actin. The protein levels 
of SR-BI (C) and ABCG1 (D) were evaluated by western blotting. Representative blots and 
quantifications of band intensities of at least 3 experiments are presented. The results are 
represented as mean  SD of at least 3 individual experiments. 
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Identification of EL modulating trans-endothelial transport 
We hypothesized that EL mediates HDL binding, cell association and transport. First we 
confirmed the expression of EL in endothelial cells by PCR (Fig. 3A) and by western blot 
analysis (Fig. 3B). Then the effect of IL-6 stimulation on EL expression was analyzed.  
After 24h stimulation with IL-6, EL expression was doubled on both the RNA level (2.12 
 0.41 fold) (Fig. 3C) and the protein level (1.98  0.84 fold, Fig. 3D) as revealed by real-
time PCR and western blotting analyses, respectively. To evaluate the role of EL in HDL 
binding we treated the cells with pharmacological inhibitors as well as by reducing its 
expression by RNA interference. Binding of HDL was reduced to 79  10 % after 
treatment of the cells with heparin. Moreover after digesting the cell surface 
proteoglycan with heparinase, binding of HDL was reduced to 65  15 %. In addition 
treating the cells with the lipase inhibitor tetrahydrolipstatin (THL) reduced the binding to 
53  22% (Fig. 4 A). Finally specific RNA interference against EL reduced binding, cell 
association and transport to 52  12%, 71  14 % and 47  8%, respectively (Fig. 4 B-
D). On the transcriptional level siRNA treatment revealed a decrease to 10 % on mRNA 
expression (data not shown) and to  50 % on protein expression compared to non-
coding siRNA transfected cells whereas the expression of SR-BI and ABCG1 remained 
unchanged (Fig. 4F).  
 
EL enhancement after IL-6 causes increase of HDL binding and 
transport  
To analyze the role of IL-6 in EL expression and consequently HDL binding and 
transport, the endothelial cells were stimulated with IL-6 and treated with THL to block 
the HDL binding to EL. The IL-6 stimulation enhanced the binding and transport of HDL 
to 140  20% and 184  30 % respectively. However THL treatment after IL-6 
stimulation reduced the binding by 65  17% and transport by 77  30% compared to IL-
6 stimulation and compared to the not stimulated cells by  50 % for both binding and 
transport. The difference between the THL treated cell with or without IL-6 was not 
significantly different for the binding and transport of HDL (Fig. 5 A and B). Moreover, IL-
6 stimulation increased the lipase activity of 130  6% in the endothelial cells (Fig. 5C). 
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To verify that the obtained activity was EL dependent the cells were transfected with 
specific siRNA against EL and resulted in a reduction off 43  30% in lipase activity 
(data not shown). Moreover endothelial cells treated with THL reduced the lipase activity 
by  50 % (Fig.  5C). These results indicated that the up regulation of EL expression is 
responsible of the enhancement of cell binding and transport of HDL through endothelial 
cell after IL-6 stimulation. 
 
 
Figure 3: Role of IL-6 on the expression of endothelial lipase. The basal expression of EL by 
endothelial cells was analyzed by PCR (A) or by western blotting (B). Effects of 24 hours 
stimulation with IL-6 on mRNA (C) and protein levels (D) of EL were analyzed by real time PCR 
or western blotting. The results are represented as means  SD of at least 3 individual 
experiments. 
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Figure 4: Role of EL in HDL binding (A, B), cell association (C) and transport (D). To 
address the role of EL, pharmacological inhibitors (A) as well as specific siRNA for EL (B-D) 
were used. The binding of HDL was assayed after 30 min pre-incubation with heparin (100 
g/ml), heparinase (0.2 U/ml) or THL (25 μM) (A) or 72 hours after siRNA transfection (B). Cell 
association (C) and transport (D) were evaluated 72 hours after the transfection. Protein 
expression of EL, SR-BI or ABCG1 (E) was evaluated 72 hours after the transfection. The 
results are represented as mean  SD of at least 3 individual experiments made of triplicates.  
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Figure 5 Role of lipolytic EL activity on the enhancement of HDL binding and transport 
after IL-6 stimulation. Cells were incubated with or without IL-6 for 24 hours in the presence or 
absence of 10 µM THL, added 30 minutes prior to the assay. Binding (A) and transport (B) were 
performed as described earlier. The endothelial lipase activity of endothelial cells (C) was 
analyzed using PED-A1. The results are represented as mean  SD of at least 3 individual 
experiments made of triplicates. 
 
EL is responsible of size reduction of HDL after cell contact. 
We previously demonstrated that HDL particles transported through a monolayer of 
endothelial cells are recovered at reduced size. Gel filtration analysis of the transported 
material demonstrated a Stokes diameter of 9.74  0.25 nm whereas the Stokes 
diameter of the starting HDL was of 10.63  0.06 nm (Fig. 6).  Interestingly, the protein 
moiety was not changed as previously demonstrated by SDS page analysis. To assess 
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if EL or SR-BI are responsible of the size reduction of HDL, we used pharmacological 
inhibitors as well as RNA interference against EL and SR-BI.  After both interference 
with SR-BI siRNA and non-coding siRNA, trans-endothelial transport led to the recovery 
of smaller particles with Stokes diameter of 9.81  0.01 nm and 10.01  0.015 nm, 
respectively (Fig. 6). In contrast, after silencing of EL, the HDL particles that were 
recovered in the basolateral compartment were less prominently and not significantly 
reduced in size (Stoke diameter of 10.25  0.12 vs. 10.63  0.05 nm for HDL without cell 
contact, Fig. 6). To corroborate this finding we blocked the lipase activity of EL with THL 
and found the size reduction of HDL abolished as well (Fig. 6). These data suggested 
that EL but not SR-BI contributes to the particle size reduction of HDL during trans-
endothelial transport. 
 
 
Figure 6: Effect of EL and SR-BI on the size reduction of HDL after cell contact. A, 
endothelial cells were cultivated on inserts, 125I-HDL was added to the apical chamber and 
incubated for one hour. HDL retrieved from the basolateral compartment after transport through 
ECs treated with indicated pharmacological inhibitors or siRNAs were analyzed by gel filtration 
chromatography and compare to HDL with cell contact. The curves represent average results of 
at least triplicate experiments (A). The bar diagrams represent means  SEM of at least 3 
individual experiments (B). 
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Discussion 
We previously reported that HDL is transported through a monolayer of cultivated 
endothelial cells in a specific process which involves SR-BI and ABGC1 3. Here, we 
assessed the question, if HDL binding, cell association and transport though the 
endothelial cells are modulated by the pro-inflammatory cytokine IL-6. IL-6 strongly 
correlates with the development of atherosclerosis 4–6 and its presence has been 
demonstrated in the atherosclerotic lesions 16.  
Inflammatory cytokines have been demonstrated to modulate trans-endothelium 
transport. For example, Dohgu et al. demonstrated an increase in HIV transport after IL-
6 stimulation whereas Wang et al. a reduction of insulin transport after IL-6 stimulation 
17,18. However to our knowledge, we demonstrate for the first time that IL-6 enhances the 
capacity of endothelial cells to bind, associate and transport HDL. Importantly 
inflammatory cytokines such as TNF, IL-1 or IL-6 have been demonstrated to 
increase the permeability of the endothelial barrier in a concentration and time 
dependent manner 19–21. Therefore in the present study, we ruled out that the 
concentration of IL-6 used, enhances transport by increasing the permeability of the 
endothelial barrier. Also unlike in human peripheral monocytes 22 IL-6 stimulation did not 
cause any changes in RNA or protein levels of SR-BI or ABCG1 in endothelial cells. 
These findings clearly indicate that the increased HDL binding and transport of HDL in 
IL-6 stimulated endothelial cells is not mediated by SR-BI or ABCG1 but by another 
protein. We hypothesized the involvement of endothelial lipase (EL) which is produced 
and secreted by endothelial cells to be subsequently bound by heparan sulphate 
proteoglycan (HSPG) in their extracellular matrix 23. After confirming the expression of 
EL in the endothelial cells its role in HDL binding and cell association, was assed using 
pharmacological treatments and RNA interference. 
Digestion of HSPG with heparinase to release the bound EL or competition for EL 
binding to HSPG with heparin reduced HDL binding on the cell surface. Moreover the 
reduction in HDL binding after blocking EL activity by the lipase inhibitor THL 
corroborates the involvement of EL in HDL binding. Interestingly, in hepatocytes it is 
reported that blocking EL by THL induces the binding of HDL 24. The role of EL in the 
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binding of HDL was further confirmed by specific RNA interference against EL and 
showed a dramatic reduction in HDL binding. Specific knockdown of EL also 
demonstrated the involvement of EL for HDL internalization and transport of HDL trough 
the endothelial cells. Similarly specific knockdown of EL was previously shown to reduce 
binding and internalization of HDL into hepatocytes 24. These results clearly indicate EL 
as an important mediator of HDL binding in endothelial cells as well as in hepatocytes. 
We previously demonstrated that the size of HDL particles decreases during trans-
endothelial transport without degradation of the protein moiety 3. Because of the 
involvement of SR-BI in trans-endothelial HDL transport one possible explanation was 
the extraction of cholesteryl esters by selective uptake. 25. Alternatively lipolysis of 
phospholipids by EL 26 may also cause the remodeling of HDL during transport. 
Therefore we investigated if SR-BI, EL or both are responsible for the HDL particle size 
reduction in endothelial cells. Specific RNA interference experiments clearly showed that 
EL but not SR-BI is responsible for HDL particle size reduction. The finding was 
confirmed by blocking the lipolytic activity of EL with THL.  
Several studies have shown that inflammation increases the level of EL on both 
endothelial cells and in the circulation 11,12,27. Therefore in the present study we analyzed 
the role of EL in the interaction of HDL with endothelial cells after IL-6 stimulation. The 
endothelial cell binding, cell association and transport of HDL after IL-6 stimulation was 
enhanced due to an enhancement of EL activity caused by up regulation of EL 
expression. Blocking EL with THL reversed the IL-6 stimulated effect. These data clearly 
indicate that IL-6 stimulates the translocation of HDL through the endothelium the first 
step in reverse cholesterol transport pathway.  
In conclusion our study demonstrated for the first time an induction of HDL binding, cell 
association and transport of HDL after IL-6 stimulation. By identifying EL as the 
endothelial target of IL6 stimulation we unraveled EL as a novel contributor to trans-
endothelial HDL transport in addition to SR-BI and ABCG1. 
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Abstract 
Objective: In the reverse cholesterol transport pathway, high-density lipoproteins (HDL) 
and their major apolipoprotein (apo)A-I pass the endothelial cell barrier by mechanisms 
involving the scavenger receptor (SR)-BI, the ATP binding cassette transporters (ATP) 
A1 and G1, the endothelial lipase (EL) and the ectopic -ATPase. However little is 
known on how inflammation influences this trans-endothelium transport.  
Approach and results: Upon stimulation with interleukin (IL)-1 or tumor necrosis 
factor (TNF) primary endothelial cells demonstrated decreased binding and transport of 
apoA-I. In addition -ATPase cell surface expression was reduced modestly reduced 
TNF but markedly decreased by IL-1. The ABCA1 expression was up regulated by 
either both cytokines. In addition, IL-1 increased the expression of ABCG1 and EL and 
decreased the expression of SR-BI whereas HDL binding or transport were not 
changed. TNF induced the expression of EL and ABCG1 as well as the binding of HDL 
to the endothelial cells. Nevertheless the specific transport through endothelial cells was 
decreased. This discrepancy between binding and transport of HDL after TNF 
stimulation was not explained by enhanced cellular HDL degradation but by reduced 
internalization.  
 
Conclusion: TNF and IL-1 reduce the translocation of apoA-I and HDL through the 
endothelium, the first step in reverse cholesterol transport pathway by regulating 
different steps in the cellular interaction of HDL and apoA-I with cells. 
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Introduction 
Atherosclerosis is the major cause of morbidity and mortality worldwide. It is 
characterized by lipid retention within the arterial wall forming atherosclerotic plaques. 
Moreover a general inflammatory state is generally associated within these plaques. 
Indeed many inflammatory markers are expressed in the plaque, among them the pro-
inflammatory cytokines: interleukin 1 (IL-1) and the tumor necrosis factor  (TNF) 1,2. 
The secretion of these cytokines is caused by the presence in the plaque of lymphocyte 
T cells and cholesterol-loaded macrophages, the macrophage foam cells 3. Many 
studies revealed the inverse correlation of high density lipoproteins (HDL) concentration 
in the plasma and the risk of atherosclerosis 4. The best investigated, potentially athero-
protective role of HDL and its major apolipoprotein (apo) A-I is their ability to remove 
cholesterol from macrophage foam cells in the arterial wall to carry it to the liver for 
excretion into the bile 5,6. An early step in the reverse cholesterol transport is the transfer 
of cholesterol from the macrophages to the lipid free apoA-I and HDL. Importantly the 
loading of cholesterol is not taking place in the plasma but in the arterial intima 6. 
Consequently HDL has to cross the endothelium to get access to the cholesterol loaded 
cells. We previously demonstrated that endothelial cells bind, internalize and transcytose 
HDL as well as apoA-I in a saturable and temperature dependent manner. Using siRNA 
and pharmacological interferences we demonstrated that endothelial cells bind and 
transport HDL by distinct specific mechanisms involving the scavenger receptor (SR)-BI, 
the ATP binding cassette transporter (ABC) G1 7 and endothelial lipase (EL) whereas 
lipid free apoA-I interact with ABCA1 and the ectopic -ATPase 8,9.   
Since atherosclerosis is an inflammatory state, we here investigated whether TNF and 
IL-1 modulate the transport of lipid free apoA-I and HDL through endothelial cells.  
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Material and methods 
Endothelial cells cultivation and treatment  
Bovine aortic endothelial cells were cultivated as previously described 8,10. Endothelial 
cells were incubated with IL-1 or TNF (Preprotech, USA) at a final concentration of 10 
ng/ml in DMEM (Sigma Aldrich) containing 0.2% BSA prior the assay for 24 or 48 hours.  
Endothelial binding, cell association and transport of HDL 
The methods for the isolation and radiolabeling of apoA-I and HDL as well as the 
quantification of endothelial binding, association, and transport of HDL have been 
described previously 7,8,10. In brief, endothelial cells were incubated with 5 g/ml of 125I-
apoA-I or 10 g/ml of 125I-HDL without (total) or with a 40 fold excess of non-labeled 
HDL (non-specific) for 1 hour at 4 °C for cell binding and at 37 °C for cell association or 
for transport studies in transwell systems. Specific binding/association/transport rates 
were calculated by subtracting the respective unspecific rates obtained in the presence 
of an excess unlabeled apoA-I or HDL as the competitors from the respective total rates 
observed in the absence of any competitor. All experiments were done in at least three 
triplicate experiments. 
HDL degradation  
The assay was performed as previously described 10. In brief, the cells were incubated 
with 10 g/ml of 125I-HDL in the absence or presence of 40-fold excess of non-labeled 
HDL. After incubation for 4 hours at 37 °C the amount of 125I-HDL degradation products 
released into the medium was measured. The proteins in the incubation medium were 
precipitated with trichloroacetic acid (TCA). To distinguish the cellular degradation 
products from the free iodine in solution after TCA precipitation, the supernatant was 
oxidized by hydrogen peroxide and the free iodine extracted with trichloroethane. The 
radioactivity in the aqueous phase containing the cellular degradation products was 
measured using a Perkin Elmer -counter.  
HDL Internalization 
The assay was performed as described above for binding and cell association studies. 
After 1 hour incubation 125I-HDL in DMEM containing hepes with 0.2 % BSA, the cells 
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were washed twice with ice-cold PBS containing 0.1 mmol/L CaCl2 and 1 mmol/L MgCl2 
and incubated on ice for 20 minutes. The cell surface proteins were biotinylated at 4 °C 
with sulfo-NSH-biotin (Pierce) (250 g/mL) in PBS (Ca2+ and Mg2+). After 1 hour the 
reaction was terminated by 10 minutes incubation with DMEM. After two additional PBS 
washes the cells were scrapped and solubilized in RIPA buffer (10 mmol/L Tris pH 7.4, 
150 mmol/L NaCl. 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, complete EDTA 
(Roche)). The supernatant was isolated after a 10 min spin at 10000 x g and a portion 
was used for total protein and radioactivity quantifications and the remained was 
incubated with streptavidin- conjugated sepharose beads (Amersham Biosciences) at 
4°C over-night. The streptavidin beads binding the cell surface proteins were 
precipitated by centrifugation and the supernatants containing the cytoplasmic proteins 
were further analyzed. The radioactivity of the supernatant was measured using Perkin 
Elmer -counter. The amount of cell surface bound HDL was calculated by subtracting 
the internalized to the total cells association.  
Endothelial cell monolayer permeability  
The tightness of the endothelial cell monolayer was assessed as 3H-Inulin filtration as 
previously described 10. In brief, endothelial cells were cultivated in transwells system for 
two days before stimulation. After 48 hours stimulation with 10 ng/ml of IL-1 or TNF, 
the permeability was measured. 3H-Inulin was added to the upper chamber and the 
medium of the lower and the upper chamber were collected after one hour at 37° C and 
measured with a -counter. Permeability was calculated as described by Youdim et al 11.  
Western Blotting 
Total proteins were analyzed after lysing endothelial cells in RIPA buffer. Cell surface 
proteins were analyzed as previously described 8,9. In brief, cell monolayers were 
biotinylated with EZ-linked Sulfo-NHS-SS-biotin (Pierce) (250 g/mL) in PBS containing 
0.1 mmol/L CaCl2 and 1 mmol/L MgCl2 at 4 °C for one hour. The reaction was 
terminated by 10 minutes incubation in DMEM at 4 °C and cells were lysed in RIPA 
buffer. The lysates were incubated with streptavidin- conjugated sepharose beads 
(Amersham Biosciences) at 4°C overnight. The beads were washed three times with the 
lysis buffer and the bound proteins were separated from the beads by incubation with 5 
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mM DTT at room temperature for one hour. Protein concentrations were determined and 
equal amounts of proteins were separated on a SDS-PAGE and trans-blotted onto a 
PDVF membrane (GE Healthcare). The protein expression was analyzed with specific 
antibodies against ABCA1 (anti ABCA1 AB.H10 ABCAM), -ATPase (anti -ATPase 
MS503 MitoScience, Eugene, OR), ABCG1 (anti ABCG1 E20 Santa Cruz), SR-BI (anti 
SR-BI E4 Novus or anti SR-BI EP1556Y ABCAM) and EL (anti EL NB 400-118 Novus) 
and compared to the expression of actin (anti-actin AC-15, Sigma). Intensity of the blot 
was quantified using Image J. 
Immunofluorescence  
Endothelial cells were seeded on cover-slides two days prior the assay. Then cells in 
DMEM with 0.2 % BSA were incubated with 50 nM of LysoTracker probe (Invitrogen) 
followed by 25 g/ml of HDL previously labeled with atto-488 (Sigma Aldrich) following 
the manufacturer’s instructions. After one hour incubation, cells were washed three 
times in PBS containing 0.1 mmol/L CaCl2 and 1 mmol/L MgCl2 and fixed with 3.75 % 
paraformaldehyde (PFA) at room temperature for 30 minutes. The fixation was stopped 
by washing with 0.5 mM Tris-HCl pH 7.4 solution for 10 minutes. After washing with PBS 
twice, cells were mounted in embedding solution containing DAPI to visualize the nuclei 
(Invitrogen). The cells were visually inspected using an axiovert 200M microscope 
(Zeiss).  
Statistical analysis 
The data for all experiments were analyzed using Graph Pad Prism 5 software program. 
Comparisons between groups were performed using t-test or ANOVA. Experiments 
were routinely performed in triplicate. The data have been obtained from at least three 
individual experiments and are graphically represent as means  standard deviation 
(SD). n.s. not significant; * P<0.05; ** P<0.001; *** P<0.0001 
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Results  
TNF and IL-1 reduce apoA-I binding and transport 
To investigate whether the interaction of apoA-I with endothelial cells is modulated by 
inflammatory cytokines we stimulated aortic endothelial cells with TNF and IL-1. The 
interactions of iodinated apoA-I with the endothelial cells were characterized as binding 
at 4 °C, cell association and transport at 37 °C. After 48 hours stimulation with the 
cytokines the specific binding was compared to not stimulated cells. It was significantly 
reduced to 73  18% and to 43  20% in TNF and IL-1 stimulated cells respectively 
(Fig. 1A). TNF and IL-1 also reduced the specific cell association of apoA-I to 77  
11% and to 74  15% respectively (Fig. 1B).  Interestingly apoA-I transport was also 
significantly reduced to 48  32% after IL-1 stimulation. In contrast the specific 
transport of apoA-I after TNF treatment was not changed significantly (84  40%) (Fig. 
1C). Previous studies reported that inflammatory cytokines induced endothelial cell 
barrier permeability. Therefore the integrity of the endothelial cells monolayer was 
assessed by analyzing the permeability with 3H-Inulin after TNF and IL-1 stimulation. 
The integrity of the endothelial monolayer was not significantly changed after IL-1 
stimulation compared to not stimulated cells, 1.683 E-5  9.10 E-7 and 1.782 E-5  7.318 
E-7 respectively. By contrast, TNF stimulation increased the permeability of the 
endothelial cell monolayer by  20% respectively 2.111 E-5  1.325 E-6 (Fig. 2).  
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Figure 1. Influence of TNF and IL-1 on specific endothelial binding at 4°C (A), cell 
association at 37°C (B), and transport of apoA-I (C). ECs were stimulated with TNF or IL-1 
(10 ng/ml) for 48 hours prior the assays. Binding (A) was measured by incubating the cells with 5 
g/ml 125I-apoA-I  40 folds excess of un-labeled apoA-I at 4 °C for 1 hour. To analyze the 
association (B) and transport (C) ECs were cultivated for 24 hours on insert before TNF or IL-
1 stimulation then 125I-apoA-I  40 folds excess of un-labeled apoA-I was added to the apical 
compartment. After one hour at 37 °C cells were lysed and specific activity was counted to 
obtain cell association (B). Medium of the basal compartment was harvested and specific activity 
was monitored to obtain the transport (C). The results represent specific binding, association 
and transport which were calculated as the differences of radioactivity recorded in the absence 
of competitor minus radioactivity recorded in the presence of competitors. They represented as 
means  SD of at least 3 individual experiments made of triplicate. 
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TNF and IL-1 do not reduce ABCA1 but reduce cell surface 
expression of -ATPase. 
Previously, we demonstrated that ABCA1 and the ectopic -ATPase modulate the 
binding of apoA-I to the endothelial cells. Therefore we analyzed by Western blotting if 
IL-1β and TNFα influence the expression of ABCA1 and -ATPase in the cells. After 48h 
the total protein expression as well as the cell surface expression level of ABCA1 was 
increased after both TNF and IL-1 stimulation (Fig. 3). In the total cell lysate no 
change in the expression of the -ATPase was observed. However on the cell surface 
the expression level was moderately reduced after TNF stimulation but markedly 
reduced after IL-1 stimulation compared to not stimulated cells.  
Figure 2. Influence of TNF and IL-1 on 
endothelial permeability. ECs were 
stimulated with TNF or IL-1 (10 ng/ml) for 
48 hours prior the assays. The permeability of 
the cell monolayer to inulin was determined. 
The results are represented as mean  SD of 
at least 3 individual experiments made of 
triplicate 
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Figure 3. Protein expression of ABCA1 and -ATPase after stimulation with TNF or IL-1 
(10 ng/ml; 48 h). The protein levels of ABCA1 and -ATPase were evaluated by western 
blotting. Cell surface proteins were differentiated from the total proteins by cell surface 
biotinylation. Representative blots and quantifications of band intensities of at least 3 
experiments are presented. The results are represented as mean  SD of at least 3 individual 
experiments 
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TNF not IL-1 modulates HDL binding, cell association and 
transport through the endothelial cells. 
To investigate whether inflammatory cytokines influence HDL binding, association and 
transport, endothelial cells were stimulated with TNF or IL-1 for 24h.  The stimulation 
of the cells with IL-1 did not change the binding, association and transport of HDL 
significantly (Fig. 4 A-C).  Interestingly, TNF-α stimulation increased binding and cell 
association of HDL to endothelial cells by 166  62% (p<0.01) and 134  29% (not 
significant), respectively compared to not stimulated cells (Fig 4 A-B). In contrast HDL 
transport was strongly reduced to 44  24% (Fig. 4 C).    
The discrepancy between increased HDL binding and decreased transport in endothelial 
cells after TNF stimulation suggested that TNF either induces intracellular HDL 
degradation or reduces HDL up-take. To analyze the first hypothesis, the degradation of 
125I-HDL was measured after TNF stimulation. However no significant enhancement of 
HDL degradation could be observed in cells stimulated with TNF-α as compared to not-
stimulated cells 10.26  0.38 and 10.33  1.15 ng/mg protein respectively (Fig. 5 A). 
This finding was further confirmed by incubating endothelial cells with fluorescently 
labeled HDL and Lysotracker probe, which revealed no co-localizing of HDL with the 
lysosomes in either TNF stimulated or in none stimulated cells (Fig. 5 B).  The 
incubation of the cells with fluorescently labeled HDL demonstrated a similar cellular 
distribution pattern of HDL in the TNF-α stimulated and not stimulated cells but the 
signal appeared to be decreased after TNF stimulation. Therefore the cellular 
distribution of 125I-HDL was analyzed by cell surface biotinylation. Interestingly, HDL cell-
association (cell surface bound and internalized HDL) was not changed after TNF 
stimulation (112  23%) compared to not stimulated cells (100%). But the internalized 
HDL was clearly reduced compared to not stimulated cells 50  5% and 66  12% 
respectively. In agreement with the previous binding studies, cell surface bound HDL 
was increased 1.8 fold after TNF stimulation (62  23%) compared to none stimulated 
cells (34  16%) (Fig. 5 C) 
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Figure 4. Influence of TNF and IL-1 on specific endothelial binding at 4°C (A), cell 
association at 37°C (B), and transport of HDL (C). ECs were stimulated with TNF or IL-1 
(10 ng/ml) for 24 hours prior the assays. Binding (A) was measured by incubating the cells with 
10 g/ml 125I-HDL  40 folds excess of un-labeled HDL at 4 °C for 1 hour. To analyses the 
association (B) and transport (C) ECs were cultivated for 24 hours on insert before TNF or IL-
1 stimulation then 125I-HDL  40 folds excess of un-labeled apoA-I was added to the apical 
compartment. After one hour at 37 °C cells were lysed and specific activity was counted to 
obtain cell association (B). Medium of the basal compartment was harvested and specific activity 
was monitored to obtain the transport (C). The results represent specific binding, association 
and transport which were calculated as the differences of radioactivity recorded in the absence 
of competitor minus radioactivity recorded in the presence of competitors. They represented as 
means  SD of at least 3 individual experiments made in triplicate. 
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Figure 5. Influence of TNF on HDL degradation (A-B) and HDL uptake (C). ECs were 
stimulated with TNF or IL-1 (10 ng/ml) for 24 hours prior the assays. Degradation (A) was 
measured by incubating the cells with 10 g/ml 125I-HDL at 37 °C for 4 hours. Intracellular 
localization of HDL (B) was monitored by incubating cell with 25 g/ml of fluorescently labeled 
HDL (green) and 50 nM of Lysotracker (red) for one hour at 37 °C (bars = 50m). Uptake (C) 
was measured by incubating the cells with 10 g/ml 125I-HDL at 37 °C. After one hour cells were 
washed and incubated with biotin as described in the method. The results are represented as 
mean  SD of at least 3 individual experiments made of triplicate. 
 
TNF and IL-1 modulate the expression of ABCG1, SR-BI and EL 
We next investigated the effect of inflammatory cytokines on the expression of ABCG1, 
SR-BI and EL in endothelial cells. The protein expression analysis by western blotting 
demonstrated that both TNF and IL-1 induce the expression of both ABCG1 and EL. 
The expression of SR-BI was reduced after IL-1β stimulation.  
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Figure 6. Protein expression of ABCG1 (A), SR-BI (B) and EL (D) after  stimulation with 
TNF or IL-1 ( (10 ng/ml; 48 h). The protein levels of ABCG1, SR-BI and EL were evaluated 
by western blotting. Representative blots and quantifications of band intensities of at least 3 
individual experiments are presented. The results are represented as mean  SD of at least 3 
individual experiments 
 
 
Discussion 
Several lines of evidence suggest the essential role of TNF and IL-1 in 
atherosclerosis development. Indeed mouse models deficient of either TNF or IL-1 
develop less atherosclerotic lesions 12–14 whereas mice exposed to an excess of 
inflammatory cytokines develop more atherosclerosis 15. Human studies also supported 
the pro-atherogenic role TNF and IL-1. Indeed circulating levels of either cytokine 
were shown to increase the risk of atherosclerotic cardiovascular events 16,17. Finally 
TNF and IL-1 are present in atherosclerotic plaques 1,2.  
The effect of inflammatory cytokines on the physiology of endothelial cells has been 
extensively studied in the last decades. We here investigated for the first time the effects 
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of TNF and IL-1 on the transport of apoA-I and HDL through endothelial cells. TNF 
and IL-1 reduced both binding and cell association of lipid-free apoA-I in endothelial 
cells. In addition apoA-I transport was reduced after IL-1 stimulation but not altered 
after TNF incubation. In agreement with previous reports 18–21 TNF increased the 
endothelium permeability by 20%. Despite this increase leakage, we did not observe any 
increase in the transport of apoA-I and HDL transport was rather decreased. This 
underscores the robustness of our method to assess specific transport of endothelial 
cells.  
Interestingly stimulation with IL-1 did not change the permeability and the transport 
capacity was reduced as expected upon the reduction in the apoA-I binding.  We 
previously reported that apoA-I binds to both ABCA1 and the ectopic -ATPase 8,9. 
apoA-I is lipidated by ABCA1 whereas it activates -ATPase to generate ADP which is in 
turn stimulates the P2Y12 receptor to signal to an as yet unknown target activating the 
uptake of lipidated apoA-I or HDL 9,22. In the present study we demonstrated that TNF 
and IL-1 induce ABCA1 expression but reduce -ATPase expression on the plasma 
membrane. Only the reduced expression of the ectopic -ATPase is in agreement with 
the reduced apoA-I binding to endothelial cells observed after IL-1 stimulation. The 
reduced cell association and transport after stimulation with IL-1 further supports the 
essential role of the apoA-I/-ATPaseP2Y12 receptor signaling for uptake of lipidated 
apoA-I or HDL. However further experiments are needed to proof, that IL-1 interferes 
with HDL transport via this cascade.  
We previously reported that upon stimulation with IL-6, HDL binding to endothelial cells 
was enhanced dependently of the up-regulation of EL which is in line with reports 
demonstrating induced EL expression in inflammation 23–25. In the present study TNF 
and IL-1 also induced EL expression. However TNF but not IL-1 enhanced HDL 
binding to the endothelial cells. This discrepancy could be explained by the reduction of 
SR-BI expression after IL-1 stimulation, which may counteract the effect of EL up-
regulation. Also TNF induced HDL binding is explained by increased EL up-regulation. 
However, despite increased binding HDL transport was reduced by TNFα due to a 
reduction of HDL internalization. Likewise TNF was demonstrated to reduce insulin 
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uptake in aortic endothelial cells 26. The discordance between increased binding of HDL 
potentially due to enhancement of EL abundance on the cell surface and reduced 
internalization points to the presence of a rate limiting step in trans-endothelial HDL 
transport which is not mediated by the as yet known HDL binding proteins SR-BI, EL 
and ABCG1.  
In conclusion our study demonstrated that the inflammatory cytokines TNF and IL-1 
reduced apoA-I and HDL trans-endothelium transport. Further experiments will be 
essential to analyze signaling pathways involve in this process.  
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Abstract 
The pathogenesis of atherosclerosis involves dysfunctions of vascular endothelial cells 
and smooth muscle cells as well as blood borne inflammatory cells such as monocyte-
derived macrophages. In vitro experiments towards a better understanding of these 
dysfunctions are typically performed in two-dimensional cell culture systems. However, 
these models lack both the three-dimensional structure and the physiological pulsatile 
flow conditions of native arteries. We here describe the development and initial 
characterization of a tissue engineered artery equivalent, which is composed of human 
primary endothelial and smooth muscle cells and is exposed to flow in vitro. Histological 
analyses showed formation of a dense tissue composed of a tight monolayer of 
endothelial cells supported by a basement membrane and multiple smooth muscle cell 
layers. Both low (LDL) and high density lipoproteins (HDL) perfused through the artery 
equivalent were recovered both within endothelial cells and in the sub-endothelial intima. 
After activation of the endothelium with either tumor necrosis factor alpha (TNFα) or 
LDL, monocytes circulated through the model were found to adhere to the activated 
endothelium and to transmigrate into the intima.  
In conclusion, the described tissue engineered human artery equivalent model 
represents a significant step towards a relevant in vitro platform for the systematic 
assessment of pathogenic processes in atherosclerosis. 
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Introduction 
Atherosclerosis is responsible for a substantial global disease load and remains a major 
cause of morbidity and mortality worldwide. One of the first events in the pathogenesis 
of atherosclerosis is the insudation of cholesterol-rich low-density lipoprotein (LDL) into 
the innermost intimal layer of the arterial wall where they are bound by proteoglycans 
and eventually modified 1. In parallel and further enhanced by the retained lipoproteins, 
the activated endothelium binds immune cells such as monocytes, which subsequently 
transmigrate the endothelium. Within the arterial intima the monocytes differentiate into 
macrophages which upon receptor mediated uptake of LDL are transformed into foam 
cells. They form the early “fatty streak” lesion 2. The inflammatory reaction of 
macrophage foam cells but also other immigrating immune cells induce the progression 
to more complicated lesions and ultimately vulnerable plaques which upon rupture or 
erosion elicit the acute complications of atherosclerosis such as acute coronary events. 
High density lipoproteins (HDL) counteract several of these pro-atherogenic activities by 
various mechanisms. The classical potentially anti-atherogenic property is related to its 
ability to remove cholesterol from the macrophage foam cells within the arterial wall and 
mediate the transport to the liver for excretion into the bile 3. To do this HDL must also 
cross the endothelial barrier in order to get access to the cholesterol-loaded 
macrophages 3. 
In addition to various in vivo models, notably genetically modified mice, 4 cell culture 
experiments have been valuable tools to unravel the above summarized 
pathomechanisms of atherosclerosis. However - so far - most of the in vitro experiments 
are performed using single types of cells grown on regular static plastic dishes. 
Importantly, these studies are associated with significant limitations, as they do not 
account for the complexity of the native artery environment with all the cell-cell and/or 
cell-matrix interactions. To address these limitations, several laboratories developed co-
culture models of endothelial cells and smooth muscle cells 5–7. However, also these 
studies were limited by the unphysiological attachment of cells to plastic dishes or trans-
well membranes and co-culture times which were too short for the development of 
typical vascular cell-extracellular matrix interactions. In the attempt to address these 
limitations, Dorweiler et al. developed a long-term co-culture setup on fibrin gels 8. In this 
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model they demonstrated for the first time the feasibility to analyses in vitro the 
accumulation of LDL and immunocytes in a sub-endothelial matrix 8,9. However, also this 
static and non-dynamic co-culture system is limited by the lack of both the circular 
structure of arteries and the physiological vascular hemodynamic situation characterized 
by flow and shear-stress. 
In recent years, several laboratories fabricated tissue engineered artery equivalents 
under pulsatile, native-like flow conditions for the therapeutic and regenerative repair of 
congenital and acquired malformations 10–13. These bioengineered autologous cell-
based constructs were also successfully implanted into large animal models and 
revealed native-like behavior and development up to 240 weeks in vivo 14. In the present 
study we used human vascular cells to engineer a 3D artery model mimicking the 
structural as well as functional characteristics of a native artery. This native-analogous 
bioengineered artery model was used to study initial events in atherosclerosis, namely 
the accumulation of LDL and HDL in the intima as well as the binding and transmigration 
of monocytes under dynamic pulsatile flow conditions. 
 
Methods  
Isolation of Umbilical cord cells  
Mature vascular cells were isolated from human umbilical cord vessels. All experiments 
were performed under cantonal ethical permission and informed consent was obtained 
from all patients [KEK-2009-95]. Human umbilical vein endothelial cells (HUVECs) and 
human umbilical cord derived myofibroblasts (UCMFBs) were isolated and characterized 
as previously described 10,14. In brief, HUVECs were isolated using the collagenase 
instillation technique. For this, the umbilical cord vessels were incubated in collagenase 
(2 mg/ml; Collagenase A; Roche Diagnostics Gmbh.) dissolved in serum-free medium 
(EBMTM; LONZA Inc., Switzerland). After 20 min of incubation, the cell suspension was 
centrifuged and isolated cells were expanded in EGMTM-2 medium (supplemented with 
VEGF, hrIGF-1, hEGF, gentamycin, amphotericin-B, hydrocortisone, ascorbic acid, 
heparin, and 2% FBS; LONZA Inc., Switzerland). For the isolation of UCMFBs the 
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remaining vessels were minced into small pieces (~2-3 mm) and incubated without 
medium under the sterile laminar flow for 25-30 min to ensure physical attachment of the 
minced pieces. Subsequently, advanced DMEM medium (Invitrogen Corp., USA; 
supplemented with 10% FBS; 0.05% Penicillin/Streptomycin, 0.02 % Fungizone and 1% 
L-glutamine) was carefully added to the minced vessel pieces and the adherent 
myofibroblastic cells were expanded up to passage 6. 
In vitro fabrication of tissue engineered vascular grafts 
Biodegradable tubular scaffold matrices (length 4 cm and inner diameter 0.6 cm) were 
fabricated as described previously10. Briefly, non-woven polyglycolic-acid meshes (PGA; 
Cellon, Luxembourg) were dip-coated with poly-4-hydroxybutyrate (P4HB; TEPHA Inc., 
USA) by dipping it into a 1.75 % (w/w) solution of P4HB/tetrahydrofuran solution (Sigma 
Aldrich). Vascular shape was obtained by heat application and a welding technique 
before external coating with 10 % P4HB/tetrahydrofuran solution. After sterilization with 
70 % ethanol (30 min) followed by 3 washes with PBS or by ethylene oxide exposition, 
PGA-P4HB composite scaffolds were pre-incubated in DMEM medium over night before 
cells seeding. UCMFBs (3-4x106 cells/cm2) were seeded in the inner surface of the 
vascular scaffold using fibrin (Sigma Aldrich) as a cell carrier 15. After a short static 
incubation period (3 days), vascular constructs were exposed to dynamic conditioning in 
a flow bioreactor system for 14 days. The flow of nutrient medium (DMEM with 10% 
FBS; 0.05% Penicillin/Streptomycin, 0.02 % Fungizone, 1 % L-glutamine and 1.5 mM L- 
ascorbic acid) was directed through their inner lumen of the bioreactor circulation loop, 
exposing the seeded constructs to an increasing flow other time (from 5 to 10 mL/min). 
Vascular grafts were then endotheliazed with HUVECs (1.5x106 cells/cm2) and cultivated 
first in static condition for 5 days in EGMTM-2 medium with supplements as described 
above. After the static phase, vascular grafts were placed back in the bioreactor for 14 
additional days with increasing medium flow (from 3 to 10 mL/min).  
Isolation and labeling of LDL and HDL  
Human LDL (1.006 < d < 1.063 kg/L) and HDL (1.063 < d < 1.21 kg/L) were isolated 
from fresh normolipidemic plasmas of blood donor by sequential gradient 
ultracentrifugation 16. The purity of the lipoprotein preparation was verified by SDS-
PAGE in order to assure no cross or albumin contamination. Freshly isolated LDL or 
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HDL was fluorescently labeled with atto-633 (Invitrogen) following manufacturer 
instructions. Fluorescent LDL (20 g/ml in EGMTM-2 medium supplemented as 
described previously) was injected in the circulatory loop of the bioreactor in the 
absence or presence of a 50 folds excess (1 mg/ml) of non-labeled LDL. After 2.5 or 24 
hours vascular grafts were removed and processed directly using confocal microscopy 
(CLSM SP5, Leica) or frozen in embedding matrix (O.C.T., Biosystem) for further 
analyses. Fluorescently labeled HDL (25 g/ml in EGMTM2 medium supplemented as 
described previously) was injected into the circulatory loop of the bioreactor system or 
injected into the medium adherently cultured cells. After 4 or 24 hours tissue engineered 
vascular grafts were removed and further processed as described for LDL.  
Isolation and labeling of monocytes  
Monocytes were isolated from healthy donors by centrifugation on a continuous density 
gradient (PercollTM; Amersham bioscience, GE health care) as described previously 17. 
Freshly isolated monocytes were fluorescently labeled with 10 M of SNARF-1 carboxyl 
acid (Invitrogen) following the manufacturer’s instructions. 1x106 monocytes per mL were 
injected into the circulation loop of the bioreactor in EGMTM-2 medium supplemented as 
described above but with 2 % of FBS. 
Histology and immunohistochemistry of tissue engineered arteries 
For histological characterization bioengineered grafts were fixed in 4%-
paraformaldehyde (PFA), dehydrated through a series of graded ethanol, embedded in 
paraffin and sectioned at 7 µm thickness. The sections were deparaffinized, rehydrated 
through a graded ethanol series. The tissue sections were stained using Haematoxylin & 
Eosin, Haematoxylin-Sudan and Masson-trichrome. Immunohistochemistry analyses 
were performed with antibodies specific for CD31 (clone JC/70A, DakoCytomation, 
Glostrup, Denmark), -smooth muscle actin (clone 1A4, Sigma) and collagen IV 
(Quartett, Germany) using the Vantana Benchmark automated staining system (Ventana 
Medicals Systems, Tucso,AZ) as previously described 10.   
Biochemical extracellular matrix analysis  
Representative tissue samples were lyophilized and analyzed by biochemical assays for 
total DNA content as an indicator for cell number, hydroxyproline (Hyp) content as an 
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indicator for collagen, as well as glycosaminoglycans (GAG) content.  For measuring the 
DNA amount, the Hoechst dye method 18 was used with a standard curve prepared from 
calf thymus DNA (Sigma Chemical Co., USA). The GAG content was determined using 
a modified version of the protocol described by Farndale et al. 19 and a standard curve 
prepared from chondroitin sulphate (Sigma Chemical Co., USA). HYP was determined 
using a modified version of the protocol provided by Huszar et al. 20. Native control 
tissues from human aorta were included and all values are presented relative to these 
native values (% of native).  
Confocal microscopy  
Bioengineered grafts were first washed twice in PBS and then fixed in 3.75 % of PFA for 
30 minutes at room temperature. Following a second series of PBS washing phases 
(3x), grafts were mounted in 0.1 M Tris-HCL, pH 9.5, and glycerol (3:7) containing 50 
mg/ml of n-propyl gallats as anti-fading reagent 21 and 1 ng/ml of DAPI to visualize the 
nuclei. Analyses of the engineered graft samples were performed on an inverted SP5 
confocal microscopy (Leica).  
Preparation of the cryopreserve sections 
Bioengineered grafts were first washed twice in PBS and then cryopreserved in 
embedding matrix (O.C.T.). The grafts were further processed on cryotome generating 
cuts with 12 m thickness. The cuts were stored at -80 °C until further processing. Cuts 
were rehydrated in PBS for 3 x 10 minutes before fixing in 3.75% of PFA for 20 minutes 
at room temperature. After three PBS washes cuts were blocked for 30 minutes in 5% 
donkey serum in PBS. For immunofluorescence staining, the cuts were incubated 
overnight at 4 °C with specific antibodies against ZO1 (33-9100, Invitrogen), ABCG1 
(HG5, Santa Cruz), SR-BI (NB 400-101 E4, Novus) or EL (NB 400-111, Novus). After 
three additional PBS washes cuts were incubated for 45 minutes at room temperature 
with secondary antibodies (Dako) followed by three additional washes with PBS and 
finally mounted in antifade solution containing DAPI (Invitrogen). The expression of 
ABCG1, SR-BI and EL were compared to a native radial artery frozen in embedding 
matrix (O.C.T.) and cut as describe above. Analyses of the cuts were performed on an 
inverted axio 200M microscope (Zeiss).  
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Endothelium integrity  
To analyses the endothelial integrity Evan’s blue (Sigma Aldrich) was injected at a final 
concentration of 0.5% in the circulation loop of the bioreactor for 10 minutes followed by 
PBS washing phase for 10 minutes. Grafts were cut open and analyzed macroscopically 
with photo documentation. 
Statistical analysis 
Statistical comparisons between different groups were performed using a paired t-test. 
The data has been obtained from at least 2 different experiments and were graphically 
represented as mean ± standard deviation of the mean (SEM). P-values of < 0.05 were 
considered statistically significant. All statistical analyses were performed using Graph 
Pad Prism-5 software. n.s. not significant; * P<0.05; ** P<0.001; *** P<0.0001 
 
Results  
Structure and characteristics of engineering arteries  
For the assessment on the structural level, the engineered artery equivalents were 
analyzed macroscopically and microscopically. Macroscopically the tube-like scaffolds 
had dimensions of 4 cm length and about 0.6 cm diameter before seeding. After the in 
vitro culture for about 5 weeks the scaffold was densely covered by cells and 
demonstrated a patent lumen (Fig. 1). Some of the grafts (15 %) showed a central 
decrease of the luminal diameter. These grafts were excluded from any further analyses.  
Microscopy analyses with Haematoxylin-Sudan and Haematoxylin-Eosin staining 
demonstrated the formation of a dense and homogenous tissue on the luminal side of 
the grafts and a loser tissue formation in contact with the degraded scaffold on the outer 
surface (Fig. 2 A-B). The tissue was composed of cells and extracellular matrix as 
demonstrated by the presence of collagen in Masson’s trichrome staining (Fig. 2 C). 
Immunohistochemistry staining showed the presence of -smooth muscle actin positive 
cells in the inner layer of the vessel and CD31 positive cells forming a monolayer on the 
luminal side (Fig. 2 D-E). Moreover, the presence of a basement membrane underneath 
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the endothelial cells was demonstrated by the presence of collagen IV positive layer 
(Fig. 2 F).   
 
 
Figure 1. Bioreactor and macrostructure of the engineered artery equivalent. A) Schematic 
view of the bioreactor set up. B) Macroscopic picture of the bioengineered artery demonstrated 
the presence of an open lumen after 5 weeks in culture as well as the formation of tissue on the 
luminal side of the graft. Bar represents 1 cm.  
 
The extracellular matrix composition of the graft was further examined with biochemical 
analyses of the presence of DNA, hydroxylproline (Hyp) or glycosaminoglycans (GAG) 
and the results were compared with the data obtained for a native human aorta. The 
GAG composition of the grafts was similar to the values observed in native tissues, 103 
± 23%. Interestingly the DNA and Hyp values represented only 39.5 ± 10% and 40 ± 
5%, respectively of the native tissue values (see Fig. 3). In summary, these results 
demonstrated that the engineered artery equivalents mimicked the cellular structures as 
well as extracellular matrix composition of a native artery. 
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Figure 2. Histological structure of an engineered artery equivalent. A) Haematoxylin-Sudan 
staining demonstrated the formation of tissue in and on the surface of a PGA/P4HB scaffold as 
well as the scaffold’s partial degradation. B) H&E staining revealed dense tissue formation 
composed of cells and extracellular matrix. C) The secretion of collagen was observed after 
Masson’s trichrome staining. The expression of -SMA (D) confirmed the smooth muscle 
phenotype of the cells in the inner layer. Collagen IV positive staining (E) demonstrated the 
secretion of basement membrane and CD31 positive staining (F) confirmed the presence of an 
endothelial cell monolayer on the luminal side of the bioengineered artery equivalent. Bars 
represent 100 m. 
 
 
 
Figure 3. Quantification of extracellular matrix 
composition and cell number. Total cell 
numbers, represented as DNA and total collagen 
secretion of collagen, represented as 
hydroxyproline (HYP) represented ≈ 50 % of the 
native human aorta.  The glycosaminoglycan 
(GAG) content was similar to native aorta. 
	 87
Endothelial integrity assessment 
Next, the integrity of the endothelium was analyzed using Evan’s blue staining. As 
expected before endothelialisation, the Evan’s blue dye was penetrating into the tissue 
and coloring evenly the bioengineered graft. (Fig. 4 A).  One week after the seeding of 
endothelial cells, the sub-endothelial tissue was less intensively stained with Evan’s 
Blue, indicating the beginning but not complete endothelialisation (data not shown). Two 
weeks after endothelial cell seeding, the tissue was not colored by Evan’s blue any more 
indicating the presence of a tight endothelium (Fig. 4 B). To confirm the presence of tight 
junctions between the endothelial cells cryopreserved tissue was stained for tight 
junction protein 1 (ZO-1). The presence of ZO-1 expression on the luminal side of the 
graft was demonstrated two weeks after endothelial cell seeding (Fig. 4 C). Taken 
together these data suggest that the endothelium of the engineered artery equivalent 
formed a functional barrier isolating the sub-endothelial tissue from the luminal fluid as 
shown with the Evan’s blue assay.  
 
Figure 4. Endothelial cells integrity in the engineered artery. The endothelial integrity was 
analyzed using Evan’s blue staining (0.5% for 10 minutes). In the absence of endothelial cell (A) 
the tissue appeared evenly stained in blue. Two weeks after endothelialization (B) the 
endothelial barrier retained the absorption of Evan’s blue and tissue appeared non-colored. The 
integrity of the endothelium was further analyzed by microscopy of cryosections for the 
expression of the tight junction protein (ZO)-1 (red) by endothelial cells (nuclei: blue). (C). Bar 
represents 50 m and L: Lumen. 
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Low-density lipoprotein insudation and accumulation in the tissue 
The insudation and accumulation of LDL into the vasculature represents early events in 
atherosclerosis development. To investigate whether our engineered artery equivalent is 
suitable to mimic this step in atherogenesis, fluorescently labeled LDL was injected into 
the circulation loop of the dynamic graft culture. The tissue was collected after 2, 5 and 
24 hours and analyzed by confocal imaging after fixation or cryopreserved for 
immunofluorescence. Confocal images were taken from the lumen of the graft and then 
– by changing the z-plane – by focusing deeper into the tissue. LDL was clearly 
localized intracellular in cytosolic vesicles within the luminal cell layer after 24 hours (Fig. 
5 A). To verify the specific uptake of LDL, the engineered grafts were incubated with 
fluorescently labeled LDL in the presence of a 50 fold excess of non-labeled LDL, the 
signal was dramatically reduced (Fig. 5 B). This observation confirms the specificity of 
the LDL up-take into the engineered artery equivalent. Cryo-sections of the graft isolated 
at 2.5 and 24 hours demonstrated a time dependent uptake of LDL by the tissue. Indeed 
the signal emitted by the fluorescent LDL increased over time (Fig. 5 C & F).  After 2.5 
hours, LDL was mainly localized within the endothelial cell layer with minimal signal in 
the sub-endothelial space (white arrow Fig. 5 C-E). After 24 hours LDL was still localized 
in the endothelial cell layer but the sub-endothelial tissue revealed an increase of 
fluorescence (white arrow Fig. 5 F). Indeed in the sub-endothelial tissue LDL was found 
to accumulate either in spots (Fig. 5 G) or diffuse areas (Fig. 5 H). These results indicate 
the possibility to study trans-endothelial transport and sub-endothelial accumulation of 
LDL in our model.  
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Figure 5. Insudation of LDL into the engineered artery. The insudation of LDL into the tissue 
(blue: nuclei) was analyzed by confocal microscopy after incubation with 20 g/ml of fluorescent 
LDL (white) for 24 hours and demonstrated the vesicular localization on the upper cell layer (A). 
The specificity of the signal was assessed by competition with 40-fold excess of non-labeled 
LDL (B). LDL localization in the tissue was further analyzed by microscopy of tissue cryosections 
and demonstrated the time-dependent uptake and the sub-endothelial localization of the LDL (C: 
2.5 hours and F: 24 hours). Zoom in of interesting regions shown with the arrows are presented 
in D and E for 2.5 hours and F and G for 24 hours. Bars represent 200 m (A-C, F) and 20 m 
(D-E, G-H) and L: Lumen. 
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Monocyte binding and insudation in engineering artery 
To investigate if our model is suitable to analyses the attachment and trans-endothelium 
migration of monocytes into the interstitial vascular tissue, labeled monocytes were 
injected into the bioreactor circulation loop and tracked by confocal imaging and cryo-
section analysis. The isolated monocytes were CD14 positive and after in vitro culture 
they express CD68 (data not shown). Monocytes were labeled with SNARF-1 dye after 
the isolation and the capacity of the labeled monocytes to bind to activated endothelial 
cells was verified in conventional cell culture (data not shown). The labeled monocytes 
were injected into the circulating medium of the graft in the absence or presence of 3 
hours pre-treatment with TNF. After 24 hours incubation, the attachment of the 
monocytes on the arterial graft was monitored by confocal imaging and demonstrated an 
increased number of monocytes adhering to the graft after TNF pre-incubation (white 
arrows; Fig. 6 A-B). Moreover after 24 hours pre-incubation of the graft with LDL, the 
monocytes attached to the endothelium to a similar extent as compared with the TNF 
pre-stimulation (Fig. 6 C). Interestingly, if the monocytes were added simultaneously 
with the LDL no increase of monocyte adhesion could be observed compared to the 
non-stimulated grafts (data not shown). In addition, the attachment of the monocytes to 
the scaffold alone was investigated and demonstrated no adhesion. To quantify 
monocyte adhesion, monocytes having remained in the circulation after 24 hours were 
counted and compared to the monocyte number of the control group (monocyte 
perfusion of scaffold only). The numbers of monocytes in the circulation after TNF and 
LDL pre-stimulation 17.5  3.0 % and 20.8  3.5 % respectively were not statically 
different (p = 0.226). However, they were significantly lower compared to the not 
stimulated engineered arteries (33,7  2,8 %), p < 0.001 for TNF and p < 0.001 for 
LDL. These results indicate that significantly more monocytes were bound under 
stimulated conditions. Microscopy of the cryo-sectioned tissue after LDL pre-incubation 
demonstrated the presence of monocytes adhering to the endothelial surface and 
migrating into the tissue (Fig. 6 E & G). In addition, monocytes were also identified in the 
tissue after LDL pre-treatment (Fig. 6 F & H-I). These results indicate that our 
engineered artery equivalent represents a suitable tool to study the attachment and 
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transmigration of monocytes into the artery, which represents a key process in the 
development of atherosclerosis in vivo.  
 
Figure 6. Endothelial monocyte adhesion and transmigration migration in the engineered 
artery. After pre-treatment in the absence (A, D) or the presence of 3 hours TNF (10 ng/ml) (B, 
D) or 24 hours LDL (20 g/ml) (C-I) 1x106 fluorescently labeled monocytes (white) per ml were 
injected into the circulation loop and circulated for 24 hours. Tissues were analyzed by confocal 
microscopy and after cryosectionning. In addition, monocytes remaining in the circulation were 
counted. More monocytes (white arrows) adhered after pre-treatment with TNF (B) or LDL (C) 
compared to the not stimulated (A). Less monocytes remained into the circulation after TNF or 
LDL pre-treatment compared to the absence of stimuli (D). Monocytes adhesion and migration in 
the tissue was further analyzed by microscopy of cryosections after LDL pre-treatment. 
Microscopic observations demonstrated adhesion and migration of monocytes through the 
endothelium (dash line) (E, G) and accumulation of monocytes into the tissue (F, H-I). Bars 
represent 200 m (A-C, E-F) and 20 m (G-I). 
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High density lipoprotein insudation in engineered artery. 
HDL is an important key player in the development of atherosclerosis development. 
Indeed HDL is believed to have a major anti-atherosclerotic potential by removing the 
excess cholesterol out of the macrophages in the arterial wall. In this context, the trans-
endothelial transport of HDL remains a potentially limiting step to be elucidated 22. The 
ATP binding cassette (ABC) G1, the scavenger receptor (SR)-BI and endothelial lipase 
(EL) were demonstrated to participate in the trans-endothelial transport of HDL in cell 
culture 23. In order to analyses HDL transport across the endothelium the expression of 
the known HDL binding proteins were investigated by immunofluorescence stainings. 
Specific stainings with antibodies against ABCG1, SR-BI and EL demonstrated the high 
expression of those markers by both HUVECs and HUMFBs in the engineered artery 
equivalent in a comparable pattern as in a native artery (Fig. 7). To further investigate 
whether our model is suitable to analyses the transport of HDL through endothelial cells, 
we incubated the bioengineered graft with fluorescently labeled HDL. Similar as 
described for LDL, cryosection of the harvested engineered arteries demonstrated the 
presence of HDL in the endothelial cells as well as the accumulation of HDL in the sub-
endothelial space (Fig. 8A). In addition, the distribution of HDL was analyzed by confocal 
microscopy. Interestingly, HDLs were localized either in intracellular vesicles or as 
extracellular diffused material if incubated with engineered arteries under flow conditions 
(Fig. 8B). However, under static non-flow conditions labeled HDL was recovered in 
intracellular vesicles only (Fig. 8 C & D). These differences between static (non-flow) cell 
culture conditions and the flow conditions of our engineered arteries demonstrates the 
potential of the proposed model to study HDL transport under in vitro in conditions which 
are closer to the native situation. 
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Figure 7. Expression of ABCG1, SR-BI and EL in the bioengineered artery in comparison 
to native artery. The expression of ABCG1 (red) (A), SR-BI (red) (C) and EL (red) (E) was 
assessed by immunofluorescence staining after cryosection of the engineered artery and 
compared to a native radial artery (B, D, F) (blue: nuclei). Bars represent 50 m. 
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Figure 8. HDL insudation in the engineered artery equivalent. 25 g/ml of HDL was 
circulated for 24 hours. The insudation of HDL (white) was assessed after cryosection of the 
tissue on the luminal side (A) and in the tissue (B) (blue: nuclei). HDL localization in the tissue 
was further analyzed by confocal microscopy at 2.5 um (C) and 16 um (D) deep in the tissue. 
The arrow shows the intracellular vesicular localization. The up-take of HDL (white) into 
HUVECs (E) and UCMFB (F) was analyzed in regular cell culture after 24 hours incubation with 
25 g/ml. Bars represent 50 m and L: Lumen 
 
	 95
Discussion  
Given its substantial negative socioeconomic impact, atherosclerosis has been 
intensively studied in the last decades. In particular, many efforts have been undertaken 
to develop an adequate ex vivo model for the biofunctional large-scale assessment of 
ethiopathogenetic phenomena in vitro. The development of endothelial and smooth 
muscle cell co-culture systems for the assessment of monocyte transmigration and 
accumulation in the artery intima, representing a key step in the pathogenesis of 
atherosclerosis, was already proposed in the early 1990’s 5,6. However, as already 
emphasized by Dorweiler et al., these co-culture systems allow neither for long term in 
vitro culture nor histology and extracellular matrix analyses 8. Their own co-culture 
system on a fibrin gel allowed longer culture times for up to 6 weeks and hence 
represented a major step forwards the in vitro modeling of atherosclerosis8,9. 
Nevertheless, in spite of this improvement, also this approach was missing a major 
physiologic aspect evident in the biology of native arteries - that is the presence of 
(pulsatile) blood flow in a lumen. This seems most important because atherosclerotic 
lesions prevail at the site of altered blood flow as first reported by Caro et al. 24.  
Therefore, the present study addressed the question whether bioengineered artery 
equivalents - as previously developed as therapeutic replacements for patients with 
structural cardiovascular disease 10–13- are suitable for modeling essential pathogenic 
phenomena of atherosclerosis in vitro. In particular, the pulsatile native-like flow 
environment could represent a major advantage in this regard when compared to 
previous studies using static cell culture environments. 
 
As previously shown, histological analyses of the bioengineered grafts demonstrated a 
structure similar to the layered microstructure of the native artery 10,14,25. These 
constructs were equally covered with a multi-layer of -smooth muscle actin positive 
cells indicating the development of a media-like layer. The presence of secreted 
extracellular matrix components, such as collagen and glycosaminglycans demonstrated 
the in situ functionality of smooth muscle cells in the tissue. However, the biochemical 
DNA and the collagen quantification, revealed lower values than found in the native 
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artery. This phenomenon has been previously described and supposed to be due to the 
relatively short in vitro culture periods 10. This is further supported by the experiments in 
large animal models, where tissue engineered arteries were exposed to longer in vitro 
and in vivo conditioning and eventually showed higher ECM values 14. The positive layer 
of collagen IV suggested the presence of a basement membrane, that is secreted by the 
endothelial cells and separates them from the sub endothelial space 26. In addition, the 
luminal side was covered with a monolayer of endothelial cells on top of the basement 
membrane. Another major function of the endothelium is the formation of a tight barrier 
between the blood and the interstitial vascular tissue. In our engineered grafts, the 
integrity of the endothelial layer was confirmed by its impermeability for Evan’s blue stain 
as well as by the expression of the ZO-1. 
 
The microscopic demonstration of labeled LDL in intracellular vesicles and the sub 
endothelial space indicate the uptake and resecretion of LDL. According to the 
response-to retention model, the accumulation of LDL in the sub-endothelial space is a 
crucial step in the formation of atherosclerotic lesions 27. Besides the accumulation of 
LDL, inflammatory processes play an indispensable role in the pathogenesis of 
atherosclerosis, for example by endothelial cell activation and subsequent monocyte 
adhesion 28. Therefore, we applied TNF to analyses monocyte adhesion to the 
endothelium. The observed significant increase of monocyte adhesion after stimulation 
with either TNF or LDL hence provides another indication that our model is feasible to 
study pathogenic events.  
 
The trans-endothelial transport of HDL in the arterial wall for removal of cholesterol 
accumulation is a key step in the reverse cholesterol transport 3. In addition, apoA-I - the 
major apolipoprotein of HDL - was found to be present in atherosclerotic plaque by 
recent investigations 29. In agreement with these histological descriptions and our 
previous findings of trans-endothelial HDL transport in transwell cell culture we found 
immunofluosecently labeled HDL both in endothelial cells and the sub-endothelial space 
of our 3D model.  
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In conclusion, we demonstrate for the first time the feasibility to engineer a dynamic 3D 
human artery equivalent for the investigation of fundamental processes involved in the 
development of atherosclerosis in vitro. In the contrary to previous investigations, this 
model combines the engineering of a native-like multilayer 3D architecture of the 
vascular wall with a lumen and the applicability of native-analogous pulsatile flow 
profiles. Thereby, this unique model mimics the native-like vascular environment and 
may therefore also allow for more representative in vitro investigations with higher 
predictive value for human pathologies in vivo. In addition, this model may also allow for 
large scale in vitro drug screening experiments – in particular by enabling the specific 
modulation of several parameters (i.e. flow, pressure, LDL, HDL, type of immune cells, 
etc). Thus, this model may ultimately help to significantly reduce the necessity of animal 
experiments in the field of atherosclerosis research. We therefore believe that our model 
represents an important step towards the development of a native-like large-scale 
atherosclerosis in vitro disease model, which may help to improve our understanding of 
this important pathology. 
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Atherosclerosis remains the major cause of morbidity and mortality in westernize-
countries, with an approximated cost of € 192 billion per year 1. A better understanding 
of the development of the disease and the mechanisms of cholesterol clearance (RCT) 
may help to developed new treatments and to reduce these costs. In the present 
dissertation the role of inflammatory cytokines on the transport of HDL and lipid-free 
apoA-I through endothelial cells, the first step in RCT, is studied together with the 
development of a novel three dimensional engineering artery model for atherosclerosis 
research.  
During RCT, HDL and lipid-poor or lipid-free apoA-I remove cholesterol out of the 
macrophage foam cells and carry it back to the liver for disposal. Several lines of 
evidence suggest that the macrophage-specific cholesterol efflux is not taking place in 
the blood circulation but rather in the arterial wall compartment 2. Therefore HDL and 
apoA-I have to cross the endothelium to get access to the cholesterol. Previously we 
demonstrated in aortic endothelial cells cultivated in an in vitro transwell system that 
HDL and apoA-I are transcytosed through endothelial cells in a process involving 
ABCG1 and SR-BI for HDL and ABCA1 and ectopic -ATPase for apoA-I 3–6. In the 
present studies, the trans-locations of HDL an apoA-I were studied in condition 
mimicking inflammation that is a hall-mark of atherosclerosis. To this end the cells were 
stimulated with IL-6, TNF and IL-1, the major cytokines found within the plaque 7,8.  
Interestingly IL-6 induced the transport of HDL through endothelial cells whereas TNF 
and IL-1 reduced the transport of both HDL and apoA-I. These cytokines were 
previously reported to have adverse effects on atherogenesis. Whereas IL-1 and TNF 
are pro-atherogenic, the role of IL-6 remains so far un-clear 9–11. Indeed both mice 
overexpressing IL-6 and IL-6-/- mice develop larger atherosclerotic lesions 12,13. 
Moreover Frisdal et al. revealed that IL-6 induces macrophage cholesterol efflux 14. 
These results suggest a possible positive effect of IL-6 in RCT from macrophages 
correlating with our results. In addition to the anti-inflammatory properties of IL-6, the 
signaling pathways of IL-6, IL-1 and TNF are different 15–17. Analyzing the pathways 
after these cytokine stimulations will permit to better understand the differences 
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observed in the transport of HDL through endothelial cells in between IL-6, IL-1 and 
TNF.   
The trans-endothelial transport of HDL after cytokine stimulations permitted to identify 
endothelial lipase (EL) as a novel HDL binding protein in endothelial cells, facilitating 
trans-endothelial HDL transport (Fig. 1). 
 
Figure 1. Trans-endothelial transport of HDL and apoA-I. EL present on heparan sulfate 
proteoglycans (HSPG) binds and partially hydrolyses HDL on the cell surface. HDL is then 
further internalized dependently of SR-BI and ABCG1. Lipids-free apoA-I binds to ABCA1 and 
gets lipidated and further internalizes by ABCA1 independent mechanisms. In addition lipid-free 
apoA-I binds to the ectopic -ATPase and signals via P2Y receptor to induce internalization of 
lipidated apoA-I and HDL. 
 
Interestingly EL was previously reported to induce HDL binding to hepatocytes 
independently of its catalytic activity via bridging of HDL 18. In the present study we 
reported that the catalytic activity is essential for HDL transport however it is not clear if 
EL has bridging function in endothelial cells. To answer this question endothelial cells 
transfected with a non-catalytic active EL will permit us to better understand the bridging 
role of EL in endothelial cells. In addition Nijstad et al. demonstrated that hepatic 
selective uptake by SR-BI involves a size reduction of HDL by EL and proposed that the 
two proteins are working sequentially in hepatocytes 23. The cooperative effect of EL 
with either SR-BI or ABCG1 in endothelial cells s is not yet clear. Co-silencing or 
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pharmacological inhibition of EL and SR-BI or ABCG1 will offer us the possibility to 
further analyze the possible sequential action of EL and SR-BI or ABCG1.  
 
The transports of HDL and apoA-I were performed in aortic endothelial cells cultivated in 
transwell system and therefore the physiological relevance of the model can be 
questioned. Therefore an ex-vivo artery equivalent was engineered with human 
endothelial cells and myofibroblasts. In this aortic equivalent physiological luminal flow 
was introduced which was missing in previous studies 24–27. Blood flow and in particular 
disturbed blood flow causing shear stress is known to be important to induce 
atherosclerotic plaque formation 28.  
In the present thesis we reported the feasibility to monitor the early steps in 
atherogenesis, meaning the insudation and sub-endothelial retention of LDL as well as 
the binding of monocytes to activate endothelial cells and their further transmigration to 
the tissue under flow conditions. Due to the production complexity and to the limited 
artery equivalents produced, the present study represents a proof of principle and further 
experiments with time and dose kinetics will be necessary to validate the present 
atherosclerotic model.  
Although the flow in our model is not equivalent to native conditions, the model 
represents a major step forward in modeling atherosclerosis ex-vivo. Future experiments 
with flow and pressure kinetics will be of particular interest in further validation 
experiments. In addition analysis of shear stress by branching in the engineered graft or 
formation of a tissue bulk to partially block the flow will provide further information. 
Moreover, the atherosclerosis model will make possible to study other atherogenic 
components e.g. lymphocyte interactions, the effect of glycation end products, reactive 
oxygen species on the endothelium, the endothelial repair process in normal and 
inflammatory conditions. Last but not least it open the possibility to investigate in more 
detail the trans-endothelium transport of HDL or apoA-I under normal or pathological 
conditions so that model will provide answers relevant for RCT.  
 
	 105
References 
1. Carson A. Atherosclerosis – The Future Challenge for Europe’s Health Economies. 
European Cardiology. 2012;5(2):86–88. 
2. Rosenson RS, Brewer HB, Davidson WS, Fayad Z a, Fuster V, Goldstein J, 
Hellerstein M, Jiang X-C, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, 
Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of 
reverse cholesterol transport. Circulation. 2012;125(15):1905–19. 
3. Cavelier C, Ohnsorg PM, Rohrer L, Von Eckardstein A. The β-chain of cell surface 
F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial 
cells. Arteriosclerosis, thrombosis, and vascular biology. 2012;32(1):131–9. 
4. Cavelier C, Rohrer L, Von Eckardstein A. ATP-Binding cassette transporter A1 
modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circulation 
research. 2006;99(10):1060–6. 
5. Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, Von Eckardstein A. High-
density lipoprotein transport through aortic endothelial cells involves scavenger receptor 
BI and ATP-binding cassette transporter G1. Circulation research. 2009;104(10):1142–
50. 
6. Rohrer L, Cavelier C, Fuchs S, Schlüter MA, Völker W, Von Eckardstein A. Binding, 
internalization and transport of apolipoprotein A-I by vascular endothelial cells. 
Biochimica et biophysica acta. 2006;1761(2):186–94. 
7. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. 
Physiological reviews. 2006;86(2):515–81. 
8. Autieri M V. Pro- and Anti-Inflammatory Cytokine Networks in Atherosclerosis. ISRN 
Vascular Medicine. 2012;2012:1–17. 
9. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, 
Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-
deficient mice. Arteriosclerosis, thrombosis, and vascular biology. 2003;23(4):656–60. 
10. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K, Seishima 
M. Disruption of tumor necrosis factor-alpha gene diminishes the development of 
atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180(1):11–7. 
11. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines 
in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2011;31(5):969–
79. 
12. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early 
atherosclerosis in mice. Arteriosclerosis, thrombosis, and vascular biology. 
1999;19(10):2364–7. 
13. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids 
induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant 
protein-1 via interleukin-6. The Journal of biological chemistry. 2001;276(3):1923–9. 
14. Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, Guerin M, Le Goff 
W. Interleukin-6 protects human macrophages from cellular cholesterol accumulation 
	 106
and attenuates the proinflammatory response. The Journal of biological chemistry. 
2011;286(35):30926–36. 
15. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Experimental and 
molecular pathology. 2001;70(3):317–25. 
16. Boekholdt SM, Stroes ESG. The interleukin-6 pathway and atherosclerosis. Lancet. 
2012;379(9822):1176–8. 
17. Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling 
pathway: A strategy to combat chronic inflammatory diseases and cancer. Cytokine & 
growth factor reviews. 2013;24(2):163–73. 
18. Strauss JG, Zimmermann R, Hrzenjak A, Zhou Y, Kratky D, Levak-Frank S, Kostner 
GM, Zechner R, Frank S. Endothelial cell-derived lipase mediates uptake and binding of 
high-density lipoprotein (HDL) particles and the selective uptake of HDL-associated 
cholesterol esters independent of its enzymic activity. The Biochemical journal. 
2002;368(Pt 1):69–79. 
19. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase is increased in vivo 
by inflammation in humans. Circulation. 2008;117(5):678–85. 
20. Paradis M-E, Badellino KO, Rader DJ, Deshaies Y, Couture P, Archer WR, Bergeron 
N, Lamarche B. Endothelial lipase is associated with inflammation in humans. Journal of 
lipid research. 2006;47(12):2808–13. 
21. Yasuda T, Hirata K-I, Ishida T, Kojima Y, Tanaka H, Okada T, Quertermous T, 
Yokoyama M. Endothelial lipase is increased by inflammation and promotes LDL uptake 
in macrophages. Journal of atherosclerosis and thrombosis. 2007;14(4):192–201. 
22. Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein 
metabolism upregulated by inflammation. Trends in cardiovascular medicine. 
2004;14(5):202–6. 
23. Nijstad N, Wiersma H, Gautier T, Van der Giet M, Maugeais C, Tietge UJF. 
Scavenger receptor BI-mediated selective uptake is required for the remodeling of high 
density lipoprotein by endothelial lipase. The Journal of biological chemistry. 
2009;284(10):6093–100. 
24. Dorweiler B, Torzewski M, Dahm M, Ochsenhirt V, Lehr H-A, Lackner KJ, Vahl C-F. 
A novel in vitro model for the study of plaque development in atherosclerosis. 
Thrombosis and haemostasis. 2006;95(1):182–9. 
25. Wada Y, Sugiyama A, Kohro T, Kobayashi M, Takeya M, Naito M, Kodama T. In 
vitro model of atherosclerosis using coculture of arterial wall cells and macrophage. 
Yonsei medical journal. 2000;41(6):740–55. 
26. Takaku M, Wada Y, Jinnouchi K, Takeya M, Takahashi K, Usuda H, Naito M, 
Kurihara H, Yazaki Y, Kumazawa Y, Okimoto Y, Umetani M, Noguchi N, Niki E, 
Hamakubo T, Kodama T. An in vitro coculture model of transmigrant monocytes and 
foam cell formation. Arteriosclerosis, thrombosis, and vascular biology. 
1999;19(10):2330–9. 
27. Navab M, Hough GP, Stevenson LW, Drinkwater DC, Laks H, Fogelman AM. 
Monocyte migration into the subendothelial space of a coculture of adult human aortic 
	 107
endothelial and smooth muscle cells. The Journal of clinical investigation. 
1988;82(6):1853–63. 
28. Caro CG, Fitz-Gerald JM, Schroter RC. Arterial wall shear and distribution of early 
atheroma in man. Nature. 1969;223(5211):1159–60.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 108
Acknowledgments 
The present thesis was performed in the Institute of Clinical Chemistry and the 
department of Regenerative Medicine at the University Hospital of Zürich and it would 
not have been possible without the help and support of a number of people. It is my 
pleasure to thank all of those who contributed, in whatever manner, to this work.  
First of all, I am highly grateful to my direct supervisor Lucia Rohrer for her constant 
support during my thesis. She gave me the opportunity to work independently while 
being present for fruitful scientific discussion and always ready to share her technical 
expertise and her knowledge in the field of lipoproteins. Despite a complicated 
beginning, Lucia encouraged and pushed me until I finally ended up with the present 
manuscript. I learned a lot through the daily contact with her and I am especially thankful 
for that.  
Furthermore I am deeply thankful to Professor Arnold von Eckardstein and Professor 
Simon Hoerstrup for giving me the opportunity to write the present thesis in their 
respective laboratories, for their supervision, and for giving me advice and guidance 
whenever needed. Special thanks go to Arnold von Eckardstein for reviewing, correcting 
and linguistically refining the present manuscript. 
Special words of thanks to Dörthe Schmidt for introducing me to the tissue engineering 
techniques at the beginning of the project and her help in general.  
I am deeply indebted to my thesis committee, Professor Roland Wenger and Professor 
Barbara Biedermann for following me during the last four years and for their advice 
throughout the project.  
I give my gratitude to my colleagues in the Institute of Clinical Chemistry; their friendship 
contributed to the nice atmosphere in the laboratory and to the success of the present 
thesis. I especially wish to thank Damir and Rahel, who started their PhDs with me, for 
their help and support as well as for trying to improve my German skills during the last 
four years. Damir was always present for scientific and photography discussions. 
Furthermore I would like to thank Silvija, who is the soul of Lucia Rohrer’s group, for her 
excellent technical help. I am obliged to Pascale for her help and for teaching me 
several methods used in the present study. I wish also to thank Diana, Wijstke and 
Srividya for the discussions during lab meetings and for their sympathy. Alaa is thanked 
for the time he spent to explain statistics to me and also Daniela for contributing to the 
kind atmosphere in the office during the writing phase. Moreover, I greatly appreciated 
the time I spent with Reda and Hans doing sports and talking in my mother tongue; 
thank you for your friendship. I sincerely appreciated working with the present and 
former members of the Institute of Clinical Chemistry: Heiko, Thorsten, Irina A, Iryna S. 
Joanna, Assem, Yu, Andrea, Carine, Seraina, Anke, Ratna and Danielle. 
	 109
 
I also give my gratitude to my colleagues in the department of Regenerative Medicine. I 
was lucky that they always considered me as a full lab member, even though my 
effective time spent in the lab was poor. I would like to thank especially Benedikt for the 
friendly work conditions and the scientific collaborations; Beni modified my opinion on 
MD PhDs. Thank you!  
In addition, I wish to thank Ursula for taking care of the ordering in the lab and Pia for 
teaching me the histology techniques. Furthermore, I warmly thank the present and 
former members of the Regenerative Medicine laboratory for their help and sympathy: 
Jaroslav, Chad, Laura, Roman, Iris, Petra, Maximilian, Debora, Agnieszka, Ajit, Martin 
and Steffen. 
Furthermore I would like to thank the secretaries, Christine Genné, Sonja Bernhard and 
Christine Schönbauer, for helping me in the administrative tasks. In addition, I thank the 
imMed program for accepting me in the PhD program and for the nice time during the 
annual meeting.  
Je souhaite remercier ma famille, premièrement mon frère Vincent pour son soutient 
durant toute la durée de ma thèse ainsi que mes parents Brigitte et Claude qui m’ont 
soutenus tant moralement que financièrement. Je n’ai pas de mots pour dire combien je 
leur suis reconnaissant et j’espère sincèrement pouvoir un jour, leur rendre tout ce qu’ils 
m’ont apporté.  
Finalement je remercie de tout cœur Audrey pour son soutient constant durant les 
moments de joie ainsi que les moments difficiles qui ont fait cette thèse. Merci!  
 
 
 
 
 
 
 
	 110
Curriculum vitae  
Personal Data 
 
Name:   ROBERT Jérôme  
Date of Birth  27.11.1983 
Nationality  Swiss, La Chaux-de-Fonds NE 
 
Education  
 
Since 2009 PhD thesis 
IMED program, University hospital Zurich, University of Zurich 
  
Institute of Clinical Chemistry  
Swiss Center for Regenerative Medicine 
 
 Supervision: Prof, A. von Eckardstein, Prof S. Hoerstrup, Dr. L. 
Rohrer 
 
2006-2008  Master of Science in functional biology 
University of Neuchâtel  
 
   Laboratory of molecular and cellular biology  
 
   Supervision: Dr. B. Mauch-Mani 
 
2003-2006  Bachelor of Science in biology, University of Neuchâtel 
    
 
2002-2003  Agrarwissenschaft  
ETH Zurich  
 
1999-2002  High School  
Lycée Blaise-Cendrars La Chaux-de-Fonds  
     
 
Work experience 
 
2008-2009  Scientific collaborator  
   University of Neuchâtel 
   Laboratory of molecular and cellular biology  
 
 
 
 
 
 
	 111
Publications 
 
Published or accepted  
 
Dijkman P.E. Weber B., Scherman J., Sanders B., Emmert M.Y., Gruenenfelder J., 
Verbeek R. Bracher M., Black M., Franz T., Kortsmit J., Modregger P. Peter S., 
Stampanoni M., Robert J., Kehl D., van Doeselaar M., Schweiger M., Brokopp C.E., 
Waelchli T., Falk V., Zilla P., Driessen-Mol A., Baaijens F.P.T., Hoerstrup S.P., Off-the-
shelf human decellularized tissue-engineered heart valves in a non-human 
primate model. Biomaterial 2013 
 
Weber B., Kehl D., Bleul B., Behr L., Sammut S., Frese L., Ksiazek A., Achermann J., 
Stranzinger G, Robert J., Sanders B., Sidler M., Proulx S., Frauenfelder T., Schönauer 
R., Emmert M.Y., Brokopp C.E., Falk V. Hoerstrup S.P., In vitro fabrication of 
autologous living bioengineered cardiovascular constructs based on prenatally 
harvested ovine amniotic fluid-derived stem cells. J. Tissue Engineering and 
Regenerative Medicine 2013 
 
Luna E., Pastor V., Robert J., Flors V., Mauch-Mani B., and Ton J., 2011. Callose 
Deposition: A Multifaceted Plant Defense Response. Molecular Plant-Microbe 
Interactions. 24, 183-193 
 
 
In revision 
 
Robert J. Lehner M., von Eckardstein A., Rohrer L., Interleukin 6 stimulates 
endothelial binding and transport of HDL through induction of endothelial lipase. 
Atheriosclerosis, Thrombosis, and Vascular Biology   
 
 
Submitted  
 
Weber B.#, Robert J.#, Ksiazek A., Wyss Y., Kehl D., Frese L., Slamecka J., Modregger 
P., Peter S., Stampanoni M., Proulx S., Falk V, Hoerstrup S.P., Living engineered 
valves for transcatheter venous valve repair. Tissue Engineering (Part C method) 
 
 
In preparation   
 
Robert J., Weber B., Frese L., Emmert M.Y., von Eckardstein A., Rohrer L., Hoerstrup 
S.P., Development of a novel 3D atherosclerosis in vitro model based on human 
tissue engineered arteries.  
 
 
 
 
	
	 112
Oral presentations 
 
1. The 2nd COST HDL annual meeting, January 27 2012 in Barcelona (Spain) 
 
2. The 2012 USGEB annual meeting, February 6 2012 in Lausanne (Switzerland) 
 
3. The 80th European Atherosclerosis Society (EAS) satellite symposium (HDL), June 2 
2012 in Milan (Italy) 
 
4. The European Lipoprotein Club (ELC) 2012, September 11 2012 in Tutzing 
(Germany) 
	
